Document:

EX-10.59

 Exhibit 10.59 

EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Exclusive License and Supply Agreement (the “LSA” or “Agreement”), dated as of September 30, 2016
(“Effective Date”), is by and between Histogen, Inc. (“Histogen”), a company organized and existing under the laws of Delaware, United States of America, and Pineworld Capital Limited, or an Affiliate of the
foregoing (“Pineworld”), a company duly incorporated under the laws of the People’s Republic of China (each a “Party”, collectively the “Parties”). 

RECITALS 
 WHEREAS,
Histogen and Pineworld executed a Terms for License and Supply Agreement, dated August 10, 2016 (the “Term Sheet”), which contains the terms and conditions pursuant to which Histogen would grant Pineworld an exclusive,
royalty-bearing license to Commercialize Product (as hereinafter defined) in the Territory (as hereinafter defined); 
 WHEREAS, Pineworld
desires to pursue the Commercialization of Product in the Territory and desires to obtain from Histogen the exclusive right and license necessary to do so, and Histogen desires to grant such rights and licenses, all under the terms and conditions
set forth in this LSA. 
 NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions contained herein, the Parties
hereto agree as follows: 
 ARTICLE 1 

DEFINITIONS 

“Affiliate” means, with respect to a Party, any person or entity directly or indirectly, through one or more intermediaries,
controlling, controlled by, or under common control with such Party. For this purpose, “control” (including the terms controlling, controlled by and under common control with) means the power whether or not normally exercised, to direct
the management and affairs of another corporation or other entity, directly or indirectly, whether through the ownership of voting securities, by contract, or otherwise. In case of a corporation, the direct or indirect ownership of fifty percent
(50%) or more of its outstanding voting securities shall in any case be deemed to confer “control”. 
 “Applicable
Laws” mean any and all laws, rules, regulations, directives, and guidances of any governmental authority, as amended from time-to-time, pertaining to the
development, manufacture, extrusion, packaging, labeling, storage, marketing, sale, import, export, distribution or intended use of any Product supplied to Pineworld under this LSA. 

“Bulk Product” means Product supplied in bulk dosage form, labeled solely with lot number identification, and before final
labeling and packaging. 
 “Business Day” means any day on which commercial banks are open for business in the United
States and/or the People’s Republic of China. 

  
 -1- 

 “CFDA” means China Food and Drug Administration, and any successor thereto.

 “Change of Control” means, with respect to either Party, (i) a merger, acquisition or consolidation with a Third
Party which results in the voting securities of that Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, acquisition or
consolidation, (ii) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of the Party,
(iii) the sale or other transfer to a Third Party of all or substantially all of the Party’s business to which the subject matter of this Agreement relates, (iv) the stockholders or equity holders of the Party shall approve a plan of
complete liquidation of the Party or an agreement for the sale or disposition by the Party of all or a substantial portion of the Party’s assets, other than pursuant to the transaction as described above or to an Affiliate, or (v) a change
in the composition of the Party’s board of directors (the “Board”) over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases by reason of one or more contested elections for
Board membership to be comprised of individuals whose election is endorsed by a majority of the members of the Board immediately before the date of election. In the case of each of sub-clauses (i), (ii) and
(iii), such Third Party shall be referred to herein as “Acquirer”. 
 “Clinical Trials” mean Phase I,
Phase II, Phase III and/or Phase IV Clinical Trials, as well as other clinical trials that may be conducted in connection with a Regulatory Approval. 

“Commercialize”, “Commercializing” or “Commercialization” means all activities directed to
the marketing, promotion, selling or offering for sale of a Product for an indication, including planning, market research, advertising, educating, marketing, promoting, importing, exporting, distributing and post-marketing safety surveillance and
reporting. 
 “Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this LSA, including
to Commercialize Product, those efforts and resources consistent with the usual practices of such Party in pursuing the development or commercialization of its own pharmaceutical products that are of similar market potential and strategic value as
such Product, taking into account all relevant factors including product labeling or anticipated labeling, present and future market potential, past performance of such Product and such Party’s other pharmaceutical products that are of similar
market potential, financial return, medical and clinical considerations, present and future regulatory environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due. Without limiting
the foregoing, Commercially Reasonable Efforts require, with respect to such obligations, that the Party apply efforts sufficient to carry out the given obligation in a diligent and sustained manner without undue interruption, pause, or delay. 

“Competing Product” means (i) with respect to the Parties, (a) any product incorporating keratinocyte growth
factor (KGF), vascular endothelial growth factor (VEGF), and/or follistatin, other than the Products, or (b) any other product incorporating any other hair growth factor, or a variety thereof, that directly
competes against HSC or (ii) with respect to an Acquirer, in the case of Section 10.2, any product incorporating keratinocyte growth factor (KGF), vascular endothelial growth factor
(VEGF), and/or follistatin. For sake of clarity, the term “Competing 

  
 -2- 

 
Product” includes any product for hair growth that (A) has one or more of the same active pharmaceutical ingredients as a Product under this LSA and (B) has not been supplied by
Histogen (or its Affiliate or related party, or Third Party on behalf of Histogen, its Affiliate or related party) to Pineworld (or its Affiliate, sublicensee or related party). 

“Control” means, with respect to any compound, product, material, information, Patent, Trademark or other Intellectual
Property right, that the Party owns or has a license to such compound, product, material, information, Patent, Trademark or other Intellectual Property right and has the ability to grant to the other Party access, a license or a sublicense (as
applicable) to such compound, product, material, information, Patent, Trademark or Intellectual Property right as provided for herein without (i) requiring the consent of a Third Party or (ii) violating the terms of any agreement or other
arrangement with any Third Party. 
 “cGMP” means current good manufacturing practices as specified in the Code of Federal
Regulations the guidance documents of the U.S. Food & Drug Administration (“FDA”), applicable to the manufacture of Product, as well as the comparable practices, regulations and documents of any other comparable regulatory
authority, in effect as of the date of manufacture of a particular batch of Product. 
 “FCPA” means the U.S. Foreign
Corrupt Practices Act (15 U.S.C. § 78dd-1, et seq.) as amended. 
 “Finished
Product” means a finished Product provided in individual dosage form suitable for direct resale. 
 “First Commercial
Sale” means the first sale of any Product in the Territory by or on behalf of Pineworld, its Affiliates or its permitted distributors to a Third Party, after receipt of Regulatory Approval for such Product in the Territory. 

“GAAP” U.S. generally accepted accounting principles, consistently applied. 

“Generic Product” means with respect to a Product in the Territory, a Third Party pharmaceutical or biological product that:
(i) contains the active pharmaceutical ingredient of the Product, and (ii) has been granted a marketing authorization by an abridged procedure that relies in whole or in part on safety and efficacy data generated for the MAA for such
Product as determined by the applicable regulatory authority in the Territory. 
 “Histogen Trademarks” means (a) the
Trademarks set forth in Exhibit 1, and (b) any other Trademarks of Histogen that the Post-Commercialization JSC determines are needed for the marketing, promotion and labeling of the Product within the Territory. 

“Huapont” means Huapont Life Sciences Co., Ltd. 

“IDL” means Import Drug License as that term may be defined by the CFDA. 

“including” (and with correlative meaning “include”) means including without limiting the generality of any
description preceding the word “including”. 

  
 -3- 

 “IND” means the equivalent application of an Investigational New Drug to
the CFDA, such as a clinical trial application or a clinical trial exemption, the filing of which is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in the Territory. 

“IFRS” means international financial reporting standards as consistently applied. 

“Intellectual Property” shall mean: (i) rights associated with works of authorship, including without limitation,
copyrights, copyrights restrictions, mask work rights, moral rights, and registrations and applications for registration of any of the foregoing, (ii) Patents, (iii) all rights related to trade secrets and
know-how, and (iv) rights analogous to those set forth herein, and any and all other proprietary rights, whether or not registrable. The term Intellectual Property does not include Trademarks. 

“Marketing Authorization Application” or “MAA” means an application to the appropriate regulatory authority,
including the CFDA, for approval to sell Product (but excluding Pricing Approval) in the Territory, including IND application and NDA. 

“Manufacturing Costs” means, with respect to a Product, the costs of creating such Product (it being understood that such
Product is considered inventory) calculated in accordance with Histogen’s internal accounting policies and principles, which are in accordance with GAAP and applied consistently to other products that Histogen produces; it being understood that
for purposes of this definition, Histogen shall mean Histogen or its Affiliate, related party, or Third Party on behalf of Histogen, its Affiliate or related party. 

“NDA” or “New Drug Application” means (i) the single application or set of applications for approval
and/or pre-market approval to Commercialize in the Territory a pharmaceutical or biologic product filed with the CFDA, and any related registrations with or notifications to the CFDA, and (ii) all
supplements and amendments that may be filed with respect to any of the foregoing. 
 “Net Sales” means with respect to a
Product for any period, the greater of (a) the total amount billed or invoiced for the Product and (b) the list price (provided, that, if the price for the Product is set by the applicable governmental authority, then the list price
shall be no less than such price) on sales of the Product during such period by Pineworld, its Affiliates, related parties or sublicensees in the Territory to Third Parties (including wholesalers or Distributors), less the following deductions, in
each case, related specifically to the Product and actually allowed and taken by such Third Parties and not otherwise recovered by or reimbursed to Pineworld, its Affiliates, related parties and/or sublicensees, or any employee, officer, director,
chairman or security holder of any of the foregoing: 
 (i) normal trade, cash and quantity discounts actually given in bona fide arm’s
length transactions; 
 (ii) bona fide, arm’s length price reductions or rebates, retroactive or otherwise, imposed by or otherwise paid
to governmental authorities or insurance payee; 
 (iii) taxes on sales (such as sales, value added, or use taxes) to the extent added to the
sale price and set forth separately as such in the total amount invoiced; 

  
 -4- 

 (iv) amounts repaid or credited by reason of rejections or defects; 

(v) the portion of administrative fees recorded by Pineworld or its Affiliate (in accordance with its standard practices and IFRS) as being
paid during the relevant time period to group purchasing organizations, pharmaceutical benefit managers and/or Medicare prescription drug plans (or equivalents thereof in the Territory) relating to such Product; 

(vi) if a Delivery System is bundled together with a Product and the total amount billed or invoiced includes both the Delivery System and
Product, then any consideration Pineworld or its Affiliate actually paid for the Delivery System related to a billed or invoiced sale of such Product; provided, that in determining the consideration Pineworld or its Affiliate actually paid
for any Delivery System, no greater discount shall be applied to the Product than is applied to the Delivery System. For purposes of this Net Sales definition, a “Delivery System” means any delivery system comprising equipment,
instrumentation, one or more devices, or other components designed to assist in the administration of such Product; 
 (vii) any invoiced
amounts from the immediately prior period which are not collected and are written off in good faith by Pineworld or its Affiliate, including bad debts, but not to exceed one percent (1%) of the gross sales during such prior period; provided,
that if any written off or written down amounts are recovered, then such amounts would constitute part of Net Sales for the period in which such amounts are recovered; 

(viii) only in the case of clause (a) above, freight, insurance and other transportation charges to the extent added to the sale
price and set forth separately as such in the total amount invoiced, as well as any fees for services provided by wholesalers and warehousing chains related to the distribution of such Product; and 

(ix) any other similar and customary deductions that are required by IFRS. 

Net Sales shall not include, to the extent for no consideration, transfers or dispositions for charitable, promotional, preclinical, clinical trial or
development, or regulatory purposes. Net Sales shall include the amount or fair market value of all other consideration received by Pineworld or its Affiliates or sublicensees in respect of the sale of Products, whether such consideration is in
cash, payment in kind, exchange or other form. Net Sales shall not include sales between or among Pineworld, its Affiliates, or sublicensees. Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and
procedures of Pineworld and its Affiliates or sublicensees, which shall be in accordance with IFRS. 
 All discounts, allowances, credits, rebates and other
deductions in the immediately foregoing clauses (i) through (ix) shall be fairly and equitably allocated to the sale of the Product by Pineworld, its Affiliates or sublicensees, such that the Product does not bear a disproportionate portion of
such deductions as compared to other products. The foregoing principle shall also apply in the event of product bundling by Pineworld, in which case, the Net Sales for a bundled product shall be calculated on a pro rata basis based on the relative
list prices of the bundled products. 

  
 -5- 

 “Patents” or “Patent Rights” mean any patents and patent
applications and all substitutions, divisionals, continuations, continuation-in-parts, any patent issued with respect to any such patent applications, any reissue,
reexamination, utility models or design patents, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all
counterparts thereof in any country. 
 “Phase I Clinical Trial” means a clinical trial in humans, the principal purpose of
which is to make a preliminary determination of metabolism, pharmacokinetics, dose findings or preliminary safety in healthy individuals or patients. 

“Phase II Clinical Trial” means a clinical trial in humans, the principal purpose of which is to make a preliminary
determination that a given product is safe for its intended use and to obtain information about such product’s efficacy sufficient to permit the design of further clinical trials, or if no further trials are necessary, to enable an MAA filing.

 “Phase III Clinical Trial” means a study in humans designed to confirm the effectiveness of a given product, monitor
side effects, compare the product to commonly used treatments, and collect information that will allow the product to be used safely. 

“Phase IV Clinical Trials” means post-marketing studies to delineate additional information about a product’s risks,
benefits, and optimal use, commenced after receipt of Regulatory Approval for a product in the indication for which such trial is being conducted. 

“Pricing Approval” means the approval, agreement, determination or decision from a governmental authority establishing the
price and/or reimbursement for Product in the Territory, as required by Applicable Laws prior to the sale of Product in the Territory. 

“Product” means a product supplied by Histogen (or its Affiliate or related party, or a Third Party on behalf of Histogen,
its Affiliate or related party) to Pineworld (or its Affiliate, sublicensee or related party) containing the Hair Stimulating Complex (“HSC”), which (1) is a soluble formulation developed by Histogen as an injectable for hair
regrowth, (2) comprises growth factors involved in hair viability such as keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and follistatin, and (3) is produced by neonatal
cells grown under simulated embryonic conditions of hypoxia (3-5% oxygen). 
 “Product
IP” means (a) the Patents as set forth in Exhibit 1 hereto (b) the Histogen Trademarks, and (c) any other Intellectual Property necessary or reasonably useful for the manufacture, use or sale of the Products that are
Controlled by Histogen or its Affiliates as of the Effective Date or at any time during the Term of the Agreement. 
 “Product
Approval” means the approval of a governmental authority necessary for the marketing and sale of Product in the Territory, which may include the approval of an MAA (but shall not include any Pricing Approvals). 

“Regulatory Approval” means all necessary approvals (including INDs, NDAs, Product Approvals, Pricing Approvals, import
permits, IDLs and, in each case any supplements and amendments thereto), licenses, registrations or authorizations of any governmental authority, necessary for the distribution, use, promotion and sale of Product in the Territory. 

  
 -6- 

 “Territory” means the People’s Republic of China (mainland). 

“Third Party” means an individual, corporation, partnership, joint venture, limited liability entity, governmental authority,
unincorporated organization, trust, association or other entity that is not related to (directly or indirectly), or an Affiliate of, a Party hereto. 

“Trademarks” means trademarks, service marks, logos, slogans, trade names, Internet domain names and any other indicator of
the source of origin of goods or services. 
 “Valid Claim” means a claim of a Patent which would be infringed (directly or
indirectly) by the research, development, manufacture or Commercialization of Product in the Territory, and which claim (i) has not been rejected, revoked or held to be invalid or unenforceable by a court or other authority of competent
jurisdiction, from which decision no appeal can be further taken, or (ii) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer. 

ARTICLE 2 
 LICENSE
GRANT 
 Section 2.1 License for Commercialization. Subject to the terms of this Agreement, Histogen hereby grants Pineworld
a limited, exclusive, personal, non-assignable (other than (a) to Huapont, (b) with Histogen’s prior written consent, or (c) in the event of a Change of Control) and non-sublicensable (other than to Affiliates, who shall use the license for fulfillment of the purpose of the LSA) license in the Territory during the Term to import, test, use, have used, register and take such
requisite actions with respect to the Product necessary to approve the Product for Commercialization in the Territory. 
 Section 2.2
License to Sell. Subject to the terms of this Agreement, Histogen hereby grants Pineworld, an exclusive, personal, non-assignable (other than (a) to Huapont, (b) with Histogen’s prior
written consent, or (c) in the event of a Change of Control), non-sublicensable (except as set forth in Section 2.3) license during the Term, after approval of a Product for
Commercialization within the Territory, to import, use, have used, sell, offer for sale, resell and distribute the Product solely in the Territory (the “Product License”). 

Section 2.3 Right to Sublicense. Pineworld may sublicense the Product License, the Trademark License (as defined hereunder) and/or
the Histogen IP License (as defined hereunder) to Affiliates providing services under the LSA without prior written approval by Histogen (provided, that any such sublicense shall terminate immediately upon the applicable sublicensee ceasing
to be an Affiliate of Pineworld), or other Third Parties pre-approved in writing by Histogen; provided, that Pineworld shall at all times remain liable for the compliance with the terms of the LSA by
any sub-licensee, and as a condition of any sub-license, such sub-licensee shall undertake in writing to comply with the terms of
this LSA such that Histogen can enforce its rights hereunder against such sub-licensee to the same extent as Pineworld; and provided further that sub-licensees
shall not be permitted to grant any further sublicenses without prior written approval by Histogen. 

  
 -7- 

 Section 2.4 Exclusivity. 

(a) Histogen hereby covenants that it shall not (and shall cause its Affiliates not to), during the Term, (i) develop (including
submitting any application(s) for product approval), manufacture, import or commercialize any Competing Product in the Territory, either on its own, with or through any Affiliate, or in collaboration with a Third Party, or (ii) cause any
Affiliate, related party, or Third Party to develop, manufacture, import or commercialize any Competing Product in the Territory. 
 (b)
Pineworld hereby covenants that it shall not (and shall cause its Affiliates not to), during the Term, (i) develop (including submitting any application(s) for product approval), manufacture or commercialize any Competing Product, either in the
Territory or outside the Territory, either on its own, with or through any Affiliate, or in collaboration with a Third Party, (ii) export Product from the Territory or Commercialize Product outside of the Territory, (iii) cause any
Affiliate, related party, or Third Party to export Product from the Territory or Commercialize Product outside of the Territory, or (iv) cause any Affiliate, related party, or Third Party to develop, manufacture or commercialize a Competing
Product. 
 Section 2.5 Prohibited Marketing and Sales. 

(a) If Histogen, its Affiliates, or a Third Party acting on its behalf, intentionally and directly develops, imports, sells, distributes,
markets, or commercializes any Competing Product in the Territory in breach of the LSA, such act shall constitute a material breach of the LSA. Failure to remedy such breach within sixty (60) Business Days after receiving written notice thereof
from Pineworld, then, following a non-appealable final determination (in accordance with Section 13.10) that Histogen has breached this provision, Histogen shall pay Pineworld 100% of
Histogen’s net profits from such breach. 
 (b) If Pineworld, its Affiliates, or a Third Party acting on its behalf, intentionally and
directly develops, imports, sells, distributes, markets, or commercializes any Competing Product, such act shall constitute a material breach of the LSA. Failure to remedy such breach within sixty (60) Business Days after receiving written
notice thereof from Histogen, then, following a non-appealable determination (in accordance with Section 13.10) that Pineworld has breached this provision, Pineworld shall pay
Histogen 100% of Pineworld’s net profits from such breach. 
 (c) If Pineworld, its Affiliates, or a Third Party acting on its behalf
export Product from the Territory or Commercializes Product outside of the Territory, such act shall constitute a material breach of the LSA. Failure to remedy such breach within sixty (60) Business Days after receiving written notice thereof
from Histogen, then, following a non-appealable determination (in accordance with Section 13.10) that Pineworld has breached this provision, Pineworld shall pay Histogen 100% of
Pineworld’s net profits from such breach. 
 Section 2.6 No Reverse Engineering. Without express prior written consent of
Histogen, none of Pineworld, its Affiliates, related parties or any Third Party acting directly or indirectly on behalf of or at the direction of Pineworld, its Affiliates or related parties shall: (i) attempt to reverse engineer the Products
or associated active pharmaceutical ingredient (“API”); nor (ii) analyze (chemically or otherwise) any Products or API except to the extent necessary to obtain Regulatory Approval or to inspect the Products for delivery. 

  
 -8- 

 Section 2.7 Right of First Negotiation. Following completion of Milestone 1,
Pineworld will have a 30 day right of first negotiation to manufacture HSC in the Territory, in the event that Histogen decides to use a Third Party to manufacture HSC in the Territory during the Term. 

Section 2.8 Reserved Rights. All rights not expressly granted to Pineworld herein are reserved to Histogen. 

ARTICLE 3 

COMMERCIALIZATION AND POST COMMERCIALIZATION 

Section 3.1 Commercialization Milestones. Commencing upon the Effective Date, Pineworld shall take all requisite and Commercially
Reasonable Efforts to register and obtain under Histogen’s name all Regulatory Approvals and approve the Product for Commercialization and sale in the Territory, including, without limitation, completing the following: 

(i) CFDA approval of the IND (“Milestone 1”). 

(ii) Completion of all Clinical Trials required for an NDA filing with the CFDA (“Milestone 2”). 

(iii) NDA filing with the CFDA (“Milestone 3”). 

(iv) NDA approval by the CFDA (“Milestone 4”). 

Section 3.2 Histogen’s Support for Commercialization. Histogen will be responsible for providing reasonable quantities of the
Product to Pineworld for Clinical Trials in the Territory and will also take Commercially Reasonable Efforts to provide reasonable scientific and technical support for regulatory and licensing efforts. As reasonably necessary to enable Pineworld to
obtain Regulatory Approvals, Histogen shall take Commercially Reasonable Efforts to provide the registration documentation, data and other information within Histogen’s Control to Pineworld promptly upon Pineworld’s reasonable request.
Histogen shall reasonably assist to answer any questions on the registration documentation that may be raised by the CFDA and other regulatory authorities. 

Section 3.3 Cost for Commercialization. Pineworld shall bear 100% of the costs and expenses in respect of the Commercialization,
including the requisite Clinical Trials and costs and fees associated with Regulatory Approval, as well as paying all Third Party labor costs (including any Third Party consulting services related to the Commercialization), shipping, travel,
subsistence and other out of pocket costs for technical and regulatory support rendered by Histogen. Pineworld will reimburse Histogen for the Manufacturing Costs of the Product used to conduct the Clinical Trials, up to a total cost of US$ 150,000.
The foregoing reimbursements and payments from Pineworld to Histogen shall be made within thirty (30) Business Days from each monthly invoice. 

  
 -9- 

 Section 3.4 Post Approval. After obtaining Product Approval in the Territory,
Pineworld will be responsible for maintaining all Regulatory Approvals within the Territory in force. If Pineworld fulfills its general obligations in this LSA, the Regulatory Approvals shall be transferred to Pineworld for the Term of the LSA.
Before such transfer, the Regulatory Approvals will remain under Histogen’s name and Pineworld shall obtain the necessary IDL. The validity period of each IDL is five (5) years, or as otherwise provided under Applicable Laws. Histogen
hereby authorizes Pineworld to renew the IDL before each expiration deadline (until the end of the Term of the LSA). 
 Section 3.5
Repackaging. Histogen hereby appoints Pineworld to apply for the registration of the local repackaging certificates, so as to enable Pineworld to repackage Product in a form suitable for resale. 

(i) Before receipt of the local repackaging certificates from CFDA, Histogen shall supply Product in Finished Product form. 

(ii) Upon receipt of the local repackaging certificates from the CFDA, Histogen shall supply the Product in Finished Product form or Bulk
Product form. If supplied in bulk, then Pineworld shall then locally repackage the Bulk Product into Finished Product. 
 Section 3.6
Safety and Recall. Histogen shall promptly inform Pineworld of any efficacy or safety issues that become known by Histogen management, or recall observed in any of its Products being marketed in other countries. Likewise, Pineworld shall
promptly notify Histogen of any complaint, problem or secondary effect or recall concerning the Products of which Pineworld becomes aware. The Party responsible for the related loss, damage, adverse effects, accidents or product liability of any
kind whatsoever shall be determined according to the circumstances of the event, including but not limited to: (i) defective quality of the Product, (ii) inaccurate advertising, (iii) marketing issues, (iv) improper storage, and
(v) infringement, and shall be responsible for and cover all costs and duties associated with said recall. 
 Section 3.7
Complaints: Pineworld shall be responsible for handling and properly addressing all customer complaints and safety reporting in the Territory, and will provide timely information to Histogen on the same. The Parties will, within thirty
(30) days of lifting of the clinical hold by the U.S. Food and Drug Administration, execute a Pharmacovigilance Agreement substantially in the form attached hereto as Exhibit 2. 

ARTICLE 4 
 JOINT
STEERING COMMITTEE 
 Section 4.1 Joint Steering Committees. The Parties shall form two joint steering committees (each, a
“JSC”) to oversee, coordinate and review recommendations and approve decisions in respect of the matters set forth hereunder, one for research, development and Commercialization (the “Regulatory JSC”), and the other
for ongoing regulatory matters, logistics and the like (the “Post-Commercialization JSC”). 
 Section 4.2
Members. Each JSC shall comprise four (4) voting members (each, a “JSC Member”). Each Party shall have the right to appoint two (2) JSC Members to serve on each JSC, where each JSC Member shall be a member of
management of the appointing Party. 

  
 -10- 

 Section 4.3 Governance. Decisions at each JSC shall be made unanimously, with a
quorum consisting of all four (4) JSC Members. In the event of a deadlock at any JSC, either Party may apply to an arbitrator to make a decision to break such deadlock. 

Section 4.4 Responsibilities of the Regulatory JSC. The Regulatory JSC shall have, inter alia, the following
responsibilities: 
 (i) Determination of timeline for the different aspects of Commercialization. 

(ii) Oversight of the entire Commercialization process, including Clinical Trials, and regulatory submissions and correspondence. 

(iii) Determination as to whether Milestone 2 has been achieved. 

(iv) Establish, review and approve the plan for the Regulatory Approval process in the Territory. 

(v) Determination of release testing criteria. 

(vi) Determination of marketing, promotion and labeling on Products. 

(vii) Facilitate a discussion on any developed Intellectual Property relating to the Products or the Commercialization. 

Section 4.5 Responsibilities of the Post-Commercialization JSC. The Post-Commercialization JSC shall have, inter alia, the
following responsibilities: 
 (i) Facilitate a discussion on any developed Intellectual Property relating to the Products or the
Commercialization. 
 (ii) Determination of marketing, promotion and labeling on Products. 

(iii) Determination of adverse event reporting requirements and related criteria. 

(iv) Oversight on logistics and transport matters. 

(v) Discussion and approval of sales forecast figures proposed by Pineworld. 

(vi) Management and oversight as to post-Commercialization regulatory matters. 

  
 -11- 

 ARTICLE 5 

MILESTONES AND ROYALTIES 

Section 5.1 Milestone Payments. Pineworld will pay Histogen the following escalating milestone payments (the “Milestone
Payments”): 
 (i) US$ 0.8 million upon completion of Milestone 1; 

(ii) US$ 1.8 million upon completion of Milestone 2; 

(iii) US$ 1.2 million upon completion of Milestone 3; and 

(iv) US$ 1.2 million upon completion of Milestone 4. 

Section 5.2 Royalties. In consideration for the Product License and the Trademark License, Pineworld shall pay (within thirty
(30) Business Days following the end of each calendar quarter) to Histogen escalating and running royalty payments on the Net Sales of Product during the Term, as follows (the “Royalty Payments” and “Royalty
Rates”, as applicable): 
 (i) For Net Sales up to and inclusive of $50 million, a Royalty Payment at a Royalty Rate of 4%.

 (ii) For Net Sales above $50 million and up to and inclusive of $125 million, a Royalty Payment at a Royalty Rate of 5.5%. 

(iii) For Net Sales above $125 million and up to and inclusive of $200 million, a Royalty Payment at a Royalty Rate of 6.5%. 

(iv) For Net Sales above $200 million, a Royalty Payment at a Royalty Rate of 7.5%. 

Section 5.3 Average Selling Price Fluctuation. In the event of a decrease or increase of 15% or more in the Average Selling Price
(as defined below) of the Product compared with the last contractual year in the Territory, the parties will negotiate in good faith as to whether an adjustment (decrease or increase) in the Royalty Rates and/or purchasing forecast is appropriate.
For the purposes hereof, “Average Selling Price” shall be the final price that the Products are actually sold by Pineworld to any end-user, excluding discounts and effects of bundling. Pineworld
shall undertake to provide all information relating to sales, on a quarterly basis, to ensure transparent determination of Average Selling Price. 

Section 5.4 Royalty Reduction. In the event that Pineworld’s market share or sales in respect of the Product significantly
decreases as determined by the JSC, due to commercial sales of a Generic Product in the Territory by a Third Party that does not involve a finally adjudicated infringement (by a competent court in the Territory and which is non-appealable) on any Patent Rights of Histogen Patent(s), then the Royalty Rate payable by Pineworld to Histogen will thereby be reduced to 50% of the otherwise applicable rate; provided, that to the extent

  
 -12- 

 
Pineworld continues to make Royalty Payments at the unreduced rates during the pendency of any litigation involving any Histogen Patent Rights, such royalty reduction shall be retroactive from
the date of CFDA approval of the Generic Product (in the form of refund to Pineworld or deduction from future payments by Pineworld, at Pineworld’s discretion) upon a final adjudication of
non-infringement and/or invalidity of one or more of such Patent Rights. Alternatively, the Parties also agree to negotiate in good faith on an adjusted Royalty Rate in the event that Generic Products reach
the market and cause Pineworld to dramatically lower its price to maintain its market share. 
 Section 5.5 Deduction. Except as
otherwise provided herein, Pineworld may not withhold payment of any amount due to Histogen because of any set-off, counter-claim, abatement, or other similar deduction. 

Section 5.6 Late Payment. If any payment due hereunder is not received within ten (10) days of its due date, Pineworld agrees
to pay a late fee equal to the lesser of: (i) 2% per month on the past due amount or (ii) the highest amount allowed by law. Pineworld shall reimburse Histogen for all costs incurred by Histogen in collecting any late payments or interest,
including attorneys’ fees, court costs, arbitration fees and collection agency fees 
 Section 5.7 Blocked Payments. In the
event that, by reason of Applicable Laws or regulations in any country, it becomes impossible or illegal for Pineworld to transfer, or have transferred on its behalf, royalties or other payments to Histogen, Pineworld shall promptly notify Histogen
of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of Histogen in a recognized banking institution designated by Histogen or, if none is
designated by Histogen within a period of 30 days, in a recognized banking institution selected by Pineworld, as the case may be, and identified in a notice given to Histogen. 

ARTICLE 6 
 SUPPLY OF
PRODUCTS 
 Section 6.1 Commercial Efforts; Reports. Following Regulatory Approval of the Product for Commercialization,
Pineworld shall (i) make Commercially Reasonable Efforts to distribute and resell the Products in the Territory, and market and promote the Products as Pineworld products, while retaining the name and logo of Histogen on packaging, as shall be
agreed by the Parties, and (ii) submit written reports within 30 days following every calendar quarter end to Histogen, showing details of sales, inventory, outstanding customer orders, orders placed by Pineworld with Histogen that are still
outstanding, royalty calculations and any other information relating to the performance of its obligations under the LSA that Histogen may reasonably require from time to time. Pineworld shall make sales of Products only in bona fide, arm’s
length transactions. 
 Section 6.2 Exclusive Supplier. Histogen will be the exclusive supplier of Product to Pineworld, and
will reasonably provide Pineworld with its requirements of the Products. Neither Party will, nor will it permit any of its Affiliates or agents, to engage in any business involving any Competing Products within the Territory during the Term
(including directly or indirectly selling or offering to sell any Competing Products in the Territory during the Term). 

  
 -13- 

 Section 6.3 Trademark License. Histogen hereby grants to Pineworld during the
Term a license in the Territory on a limited, non-exclusive, personal, fully paid, royalty free, non-assignable (other than to (a) Huapont, (b) with Histogen’s
prior written consent, or (c) in the event of a Change of Control), and non-sublicensable (except as set forth in Section 2.3) basis to the Histogen Trademarks (the
“Trademark License”); provided, that Pineworld shall obtain Histogen’s prior written approval for all such uses of Histogen Trademarks, which prior approval shall not be unreasonably withheld by Histogen. Pineworld will
provide Histogen at least thirty (30) days’ prior written notice to allow review prior to releasing any such usage. Notwithstanding anything to the contrary, all use of Histogen Trademarks shall be subject to Histogen’s internal usage
policies, which may change from time to time. Histogen shall solely retain all goodwill and intellectual property rights associated with the Histogen Trademarks and all related Trademarks derived therefrom, and the Trademark License shall be subject
to customary restrictions on usage. 
 Section 6.4 Supply Forecasts. Pineworld will provide Histogen with the following not less
than nine (9) months prior to First Commercial Sale: 
 (i) A 3-year nonbinding forecast,
updated annually. 
 (ii) An annual forecast updated 180 days prior to the commencement of each calendar year (the “Annual
Target”), where the following shall apply: 
  

	 	1.	 Pineworld shall be required to purchase more than 80% of the amount forecasted in the Annual Target.

  

	 	2.	 Each Annual Target shall include quarterly forecasts for shipments, so as to guide Histogen’s production
and manufacturing timing of the Product each quarter. 

  

	 	3.	 In the event more than 80% of the Annual Target is not purchased by Pineworld in a calendar year, Pineworld
agrees to pay Histogen an amount equal to 50% of the dollar value difference between: (x) the actual purchases by Pineworld in said calendar year, and (y) the minimum purchases required to have exceeded 80% of the Annual Target. Such
payment shall be made within 60 days of the end of the calendar year. 

 Section 6.5 Lead Time. Pineworld will
provide Histogen with a 180-day lead time on all approved purchase orders. Such period may be shortened in the future by good faith negotiations between the Parties as manufacturing, inventory, and shelf life
details become available during Product development. 

  
 -14- 

 Section 6.6 Product Pricing. After Product Approval is obtained, Histogen will
supply the Products in accordance with the following pricing schemes: 
 (i) For Finished Product, at a transfer price (ex-factory price) of Manufacturing Costs plus 80%. 
 (ii) For Bulk Products, at a transfer price (ex-factory price) of Manufacturing Costs plus 80% plus the Bulk Markup Percentage (defined below); provided, that the Bulk Markup Percentage shall not exceed 20%. 

“Bulk Markup Percentage” is an amount equal to the result of the following, expressed as a percentage: (X) the
difference in the actual Manufacturing Costs of the Finished Product (FP) and the Bulk Product (BP), divided by (Y) the Manufacturing Costs of the Finished Product (FP), multiplied by (Z) 0.8, as represented by the following formula: 

(Z)*(X/Y) = 0.8*[(FP-BP)/FP] 

For example, if the Finished Product (FP) has a Manufacturing Cost of $200/unit and the Bulk Product (BP) has a Manufacturing Cost of
$180/unit, the Bulk Markup Percentage would be: 
 0.8*([200-180]/200) = 0.08 = 8% 

Therefore, the transfer price of the Bulk Product would be the Manufacturing Costs plus (80% + 8%). 

Section 6.7 Pricing Update. The price shall be updated by Histogen in good faith, on an annual basis, to account for changes in
Manufacturing Costs, inflation and market changes. The Parties will discuss in good faith potential sharing in future cost reductions. 

Section 6.8 Payments. Payments will be made, in two tranches, fifty percent (50%) upon placement of an order with Histogen, and
the remaining fifty percent (50%) balance will be due forty five (45) Business Days from delivery of the Products for such order. 

Section 6.9 Release Testing. The Parties shall negotiate in good faith and agree on criteria for mutual release testing of Product
prior to first shipment. No orders of the Products shall be placed until Pineworld and Histogen confirm that the release testing criteria have been agreed to. No orders of Products shall be shipped by Histogen or resold by Pineworld until release
testing has been successfully completed. 
 Section 6.10 Delivery. EXW (Incoterms 2015) Histogen manufacturing/storage
facilities. Pineworld will, at its expense, appoint a carrier and insure product in transit. 
 Section 6.11 Receipt of
Products. Pineworld shall receive Products in its warehouse, and shall stock, market, promote, distribute and handle as per normal industry standards and follow any special instructions provided by Histogen, including insulation, temperature
modifications, humidity, and refrigeration conditions. If any problems are caused by non-compliance of these directions, Pineworld shall, and Histogen shall not, be held liable in such instances. 

  
 -15- 

 Section 6.12 Defective Products. Pineworld shall have forty-five
(45) Business Days from delivery to its warehouse to inspect and reject the Products delivered, and otherwise will be deemed accepted as fulfilling warranties. Pineworld may reject the Products if it is rejecting a shipment or a portion thereof
due to obvious physical damage, obvious packaging defect or quantity discrepancies that are evidence upon visual inspection of the Products. Pineworld may also reject Products by reasons of non-compliance with
the Specifications, the release testing criteria of Section 6.9, regulatory requirements or Applicable Law. Pineworld shall notify Histogen in writing of such discovered defect or
non-compliance. 
 In the event of rejection of any Products in accordance with the above, the
following shall apply: (i) in the event that Histogen agrees with the findings of Pineworld in respect of such defects in the Product, it will be required to replace such Products without any additional consideration or refund the amount paid
by Pineworld in respect of such Products; or (ii) in the event that Histogen disagrees with the findings of Pineworld in this respect, it may obtain and send samples of Products alleged to be defective to a mutually agreed upon independent
institute or laboratory of international repute for testing. Both Parties agree to cooperate with the independent institute or laboratory’s reasonable requests for assistance in connection with its analysis hereunder. The findings of such
institute or laboratory shall be final and the cost of such analysis and findings will be borne by the losing Party. Where Histogen is the losing Party, Pineworld has the discretion to have the defective Products repaired or replaced, or receive a
refund on the defective Products. 
 ARTICLE 7 

AUDIT AND INSPECTION RIGHTS 

Section 7.1 Audit by Histogen. Histogen will have the right to itself, or via a Third Party, audit and inspect the applicable
financial records and related documents and facilities of Pineworld and/or any relevant Affiliate or sublicensee, solely in connection with Products and solely to the extent such Affiliate or sublicensee holds a Product License or a sublicense
thereof, twice a year (or if reasonably required, more frequently), upon reasonable prior written notice, to ensure Pineworld’s compliance with the terms of this Agreement. 

Section 7.2 Cost of Audit by Histogen. The cost of the audit and inspection will be borne by Histogen, unless the audit reveals an
underpayment of Royalty Payments of five percent (5%) or greater for the period under audit, in which case, Pineworld shall cover the cost. 

Section 7.3 Underpayment to Histogen. In the event that Histogen discovers any underpayment of Royalty Payments on the part of
Pineworld, such underpayment shall be subject to a late fee measured from the date that full payment should have been paid as follows: 1% of the underpayment amount per month if the underpayment is 5% or less for the period under audit, and 2% per
month if the underpayment is more than 5% for the period under audit. In no event shall interest exceed the maximum legal rate under Applicable Laws. 

Section 7.4 Audit by Pineworld. Pineworld will have the right to itself, or via a Third Party, audit and inspect the applicable
financial records and related documents and facilities of Histogen and/or any relevant Affiliate or related party, solely for the purpose of determining Manufacturing Costs, twice a year (or if reasonably required, more frequently), upon reasonable
prior written notice, to ensure Histogen’s compliance with the terms of this Agreement. 

  
 -16- 

 Section 7.5 Cost of Audit by Pineworld. The cost of the audit and inspection
will be borne by Pineworld, unless there has been a overreporting of the Manufacturing Costs of five percent (5%) or greater for the period under audit, in which case, Histogen shall cover the cost. 

Section 7.6 Overreporting by Histogen. In the event that there has been an overreporting of the Manufacturing Costs on the part of
Histogen that results in an overpayment by Pineworld, such overpayment shall be refunded to Pineworld and shall be subject to a late fee measured from the date of the overpayment as follows: 1% of the overpayment amount per month if the overpayment
is 5% or less for the period under audit, and 2% per month if the overpayment is more than 5% for the period under audit. In no event shall interest exceed the maximum legal rate under Applicable Laws. 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

Section 8.1 Product Warranties. Histogen hereby warrants and represents, that upon delivery of the Products: 

(i) the Product will be manufactured, labeled, packaged, stored, tested, documented, released and shipped in accordance with cGMP and other
Applicable Laws and regulatory requirements; 
 (ii) will meet the Product specifications agreed to by the Parties and approved by the JSC
(such specifications, the “Specifications”); and 
 (iii) the Product will be free from material defects in materials and
workmanship. 
 Section 8.2 Additional Warranties. Histogen additionally represents and warrants that as of the Effective Date,
to its knowledge: 
 (i) it has the corporate authority to enter into this Agreement and to perform its obligations hereunder; 

(ii) entering into this Agreement and performing the obligations hereunder will not conflict with (A) its organizational documents,
(B) its material contracts, or (C) Applicable Law; 
 (iii) it has full right, title and interest in the Product, the Histogen
Trademarks, and the underlying Product IP that are subject to the license grants set forth herein, free and clear of any and all liens, mortgages, pledges, adverse claims, charges, security interests, encumbrances or other restrictions or
limitations whatsoever; 

  
 -17- 

 (iv) it has provided full, accurate and complete disclosure to Pineworld of all material
information relating to the Product, the Histogen Trademarks, and the underlying Histogen IP as required for the Product License, and Trademark License; 

(v) it has not granted and will not grant licenses or other rights under the Product, the Histogen Trademarks, and the underlying Product IP
within the Territory that are in conflict with the terms and conditions of the LSA; 
 (vi) the Trademark License and Product License covers
all Intellectual Property of Histogen necessary for the import, use, sale and distribution of the Product. 
 (vii) it is not aware of any
infringement or threatened infringement of the Histogen Trademarks or the Histogen IP by a Third Party; 
 (viii) the making, using and/or
selling of the Product in the Territory as of the Effective Date does not infringe any Valid Claim of any Intellectual Property right of any Third Party; and 

(ix) none of the Product IP is invalid or unenforceable. 

Section 8.3 Representations and Warranties of Pineworld. Pineworld hereby warrants and represents, that as of the Effective Date,
to its knowledge: 
 (i) it has the corporate authority to enter into this Agreement and to perform its obligations hereunder; 

(ii) entering into this Agreement and performing the obligations hereunder will not conflict with (A) its organizational documents,
(B) its material contracts, or (C) Applicable Law; and 
 (iii) it is financially solvent and has, by itself or through an
Affiliate or a related party, the financial resources and capabilities to perform its obligations under this Agreement. 
 Section 8.4
No Other Warranties. EXCEPT AS EXPRESSLY STATED HEREIN, All other warranties, WHETHER EXPRESSED OR IMPLIED BY STATUTE, COMMON LAW, OR OTHERWISE, including WITHOUT LIMITATION THE implied warranties OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, are excluded and disclaimed. All Product warranties shall be subject to normal use restrictions, and Histogen shall not be liable for any defect due to bad storage conditions, transport mishandling or any cause on the part of Pineworld, its
employees, agents, sales representatives, carriers or other Third Parties appointed by Pineworld. The sole remedy for any PRODUCT warranty claim will be repair or replacement of the defective Product, or a refund, at Pineworld’s discretion.

  
 -18- 

 ARTICLE 9 

INDEMNIFICATION; THIRD PARTY CLAIMS 

Section 9.1 Indemnification by Pineworld. Pineworld shall indemnify and hold Histogen, its Affiliates, and their respective
directors, agents and employees harmless from and against any and all liabilities, losses, damages, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) arising in connection with any
and all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a Third Party (each a “Third Party Claim”) resulting or otherwise
arising from (i) Pineworld’s distribution, marketing and promotion of the Products in and for the Territory, (ii) the breach of any obligations hereunder by Pineworld or (iii) the intentional act or omission or the negligence of
Pineworld, except to the extent that such liabilities, demands, damages, or losses arise or result from the intentional act or omission or the negligence of Histogen. 

Section 9.2 Indemnification by Histogen. Histogen shall indemnify, defend and hold Pineworld, its Affiliates, and their respective
directors, agents and employees harmless from and against any and all Losses arising in connection with any and all Third Party Claims resulting or otherwise arising from (i) the development, manufacture and/or supply of the Product by or under
the control of Histogen, (ii) the breach of any obligations or warranties hereunder by Histogen, (iii) the infringement of any Patent or other Intellectual Property rights of a Third Party in connection with the using, importing or selling
of the Product by Pineworld (as set forth below in the Third Party claims provision hereinabove), (iv) the infringement of any Trademark rights of a Third Party in connection with the use of the Histogen Trademarks on or in connection with the sale
or other Commercialization of the Product within the Territory, or (v) the intentional act or omission or the negligence of Histogen, except to the extent that such liabilities, demands, damages, or losses arise or result from the intentional
act or omission or the negligence of Pineworld. 
 Section 9.3 Indemnification Procedures. 

(a) Notice of Claim. All indemnification claims under Section 9.1 or 9.2, as applicable, will be made
solely by the corresponding Party seeking indemnity (collectively, the “Indemnified Parties” and each an “Indemnified Party”). The Indemnified Party will give the indemnifying Party (the “Indemnifying
Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses and any legal proceeding initiated by a Third Party against the Indemnified Party as to which the Indemnified Party intends to make a request
for indemnification under Section 9.1 or 9.2, as applicable, but in no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice except to the extent that such
delay actually prejudices the defense of such proceeding. Each Indemnification Claim Notice shall contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such
time). Together with the Indemnification Claim Notice, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnified Party in connection with the Third
Party Claim. 

  
 -19- 

 (b) Control of Defense. At its option, the Indemnifying Party may assume the defense
of any Third Party Claim subject to indemnification as provided for in Section 9.1 or 9.2, as applicable, by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying
Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects, and such Indemnifying
Party shall thereafter continue to defend such Third Party Claim in good faith. Should the Indemnifying Party assume the defense of a Third Party Claim (and continue to defend such Third Party Claim in good faith), the Indemnifying Party will not be
liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim, unless the Indemnifying Party has failed to assume the defense
and employ counsel in accordance with this Section 9.3. 
 (c) Right to Participate in Defense.
Without limiting the foregoing, any Indemnified Party will be entitled to participate in the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided,
however, that such employment will be at the Indemnified Party’s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to
assume the defense (or continue to defend such Third Party Claim in good faith) and employ counsel in accordance with this Section 9.3, in which case the Indemnified Party will be allowed to control the defense at the
Indemnifying Party’s expense. 
 (d) Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnified Party (i) becoming subject to injunctive or other relief or (ii) admitting any breach or violation of contract or law, the Indemnifying Party will have the
sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that such
terms shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto). With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense
of the Third Party Claim in accordance with Section 9.3(b), the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided,
it obtains the prior written consent of the Indemnified Party (which consent will be not be unreasonably withheld, conditioned or delayed). The Indemnifying Party that has assumed the defense of (and continues to defend) the Third Party Claim in
accordance with Section 9.3(b) will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the written consent of such Indemnifying Party. Regardless of whether the
Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the Indemnifying Party the
opportunity to assume the defense of the Third Party Claim in accordance with Section 9.3(b). 
 (e)
Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such
records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, 

  
 -20- 

 
trials and appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party
to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually convenient basis to
provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket expenses incurred in connection with such cooperation. 

(f) Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable costs and expenses, including fees and
disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the
Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

Section 9.4 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE FOR ANY INCIDENTAL, CONSEQUENTIAL (INCLUDING WITHOUT LIMITATION
LOST PROFITS OR REVENUES), INDIRECT, PUNITIVE, SPECIAL, OR LIQUIDATED DAMAGES OF ANY KIND UNDER OR IN CONNECTION WITH THIS AGREEMENT, OTHER THAN IN THE EVENT OF INTENTIONAL MISREPRESENTATION, FRAUD OR WILLFUL MISCONDUCT. THE TOTAL AND AGGREGATE
DAMAGES FOR WHICH EITHER PARTY MAY BE LIABLE UNDER THIS LSA SHALL BE CAPPED IN THE AGGREGATE TO AN AMOUNT EQUAL TO US $8 MILLION, OTHER THAN IN THE EVENT OF INTENTIONAL MISREPRESENTATION, FRAUD OR WILLFUL MISCONDUCT. THE FOREGOING CAP SHALL NOT
APPLY TO PINEWORLD’S PAYMENT OBLIGATIONS HEREUNDER. 
 Section 9.5 Insurance. During the Term, each Party shall procure,
provide a certificate of insurance of, and maintain insurance, including general liability insurance and product liability insurance, adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent
companies similarly situated at least thirty (30) days prior to when Product is being clinically tested in human subjects (in the case of clinical trial insurance) or commercially distributed or sold (in the case of product liability insurance)
by such Party pursuant to this Agreement. The insurance companies providing coverage must have a current A.M. Best rating of B or better and each Party shall maintain such insurance for a minimum of 1 year after the end of the Term. Notwithstanding
the foregoing, if this LSA is transferred to Huapont, then Huapont may self-insure. 
 ARTICLE 10 

TERM AND TERMINATION 

Section 10.1 Term. The term of the LSA is twenty (20) years unless earlier terminated in accordance therewith (the
“Initial Term”), with automatic renewal for two (2) additional five (5) year terms (each a “Renewal Term”, and together with the Initial Term, the “Term”), unless otherwise terminated by a
Party within one year prior to the commencement of a Renewal Term. 

  
 -21- 

 Section 10.2 Right to Terminate by Histogen. Histogen has the right to terminate
the LSA as follows (immediately upon notice other than as specifically provided below and without penalty or financial requirement): 
 (i)
In the event that, Milestone 1 is not completed (and such is not primarily due to failure on the part of Histogen) within 24 months of reaching the United States Phase II Clinical Trial 24-week time-point for
safety and clinical efficacy in men; provided, that Pineworld shall have ninety (90) days to cure after receiving notice thereof from Histogen; 

(ii) During the period between the achievement of Milestone 1 and prior to the achievement of Milestone 3, there is a period greater than 24
months during which neither a JSC-approved Clinical Trial nor an NDA filing or review by CFDA is in progress; 

(iii) If there occurs a Change of Control in Pineworld and (A) the Acquirer elects not to further develop and/or market the Product or
(B) the Acquirer is developing and/or marketing a Competing Product; 
 (iv) In the event Pineworld materially breaches the principal
terms of the LSA which results in the purpose of the LSA not being substantially achieved, and fails to remedy such breach within sixty (60) days after receiving notice thereof from Histogen; 

(v) By notice from Histogen to Pineworld if, due to reasons not under Histogen’s control, Pineworld’s purchase level of the Products
in the Territory, starting from the 3rd calendar year following Regulatory Approval, remains below 30% of Annual Target for two consecutive years; 

(vi) If Pineworld abandons Commercialization; 

(vii) In the event that annual sales of the Product by Pineworld fail to exceed (a) US$10 million in years 5, 6 or 7 following
Regulatory Approval, or (b) US$ 20 million per year after the seventh year after Regulatory Approval; 
 (viii) If all obligations
under the LSA fail to pass onto Huapont Life Sciences Co., Ltd. within 90 days following the completion of Milestone 1, such failure being curable within 45 days following receipt of notice of such failure from Histogen; or 

(ix) If Pineworld sells, or causes to be sold, the Product outside of the Territory or a Competing Product. 

provided, however, that (A) with respect to failures in years 5, 6 or 7 following Regulatory Approval, Pineworld may cure
any particular year’s failure by paying Histogen $400,000 less any Royalty Payments previously paid in respect of such failure year, and (B) with respect to failures in year 8 following Regulatory Approval and subsequent years, Pineworld
may cure any particular year’s failure by paying Histogen $600,000 less any Royalty Payments previously paid in respect of such failure year; 

  
 -22- 

 further provided, however, that in the event that a new Generic Product
that is not directly or indirectly controlled by Pineworld or its Affiliates comes to market thereby causing a significant sales decrease in the sales of the Product after the seventh year following Regulatory Approval, and as a result of such
Generic Product, Pineworld fails to reach sales of US$ 20 million in such year, then, following Histogen’s right of investigation, the minimum annual Royalty Payment for such year shall be reduced to $500,000 and for years to follow until
a year in which Product quarterly sales cease to decrease, and begin to increase again. 
 Section 10.3 Right to Terminate by
Pineworld. Pineworld has the right to terminate the LSA (immediately upon notice other than as specifically provided below and without penalty or financial requirement): 

(i) In the event that it is not commercially feasible to pursue the development, launch or sale of the Product despite good faith reasonable
efforts, in which case Pineworld may terminate effective upon written notice thirty (30) days after Histogen’s receipt of such notice; 

(ii) In the event Histogen materially breaches any of the provisions of this Agreement which results in the purpose of this LSA cannot be
substantially achieved, and fails to remedy such breach within sixty (60) days after receiving notice thereof from Pineworld; or 

(iii) If Histogen sells, or causes to be sold (other than through Pineworld or its Affiliate or related party or sublicensee), a Competing
Product in the Territory. 
 Section 10.4 Termination due to Bankruptcy. Either Party may terminate upon thirty
(30) days’ written notice if the other Party: (i) becomes subject to a voluntary petition in bankruptcy or any voluntary proceeding relating to insolvency, receivership, liquidation, or composition for the benefit of creditors,
(ii) becomes subject to an involuntary petition regarding the foregoing that is not dismissed within 60 days after filing, (iii) declares or admits publicly and in writing that it is insolvent or is unable to meets its debts as they
mature, or (iv) makes an assignment for the benefit of all or substantially all of its creditors. Notwithstanding anything to the contrary, a dissolution for the purposes of reorganization shall not trigger termination rights under this Section
and if either Party is able to fulfill its commitments under the LSA notwithstanding the foregoing clauses (i)-(iv), then no right of termination shall be triggered. 

Section 10.5 Effect of Termination. Upon termination of the LSA for any reason, (i) all clinical data and market information
and Marketing Authorization shall be transferred to Histogen; (ii) all licenses granted herein, including the Product License, Histogen IP License (as defined in Section 11.2) and Trademark License, shall immediately
terminate; and (iii) Pineworld will cease all sales and marketing activity in respect of the Product. Both Parties shall cooperate with one another in good-faith in respect of any post-termination transitions (including without limitation
repurchase of inventory, transfer of all information to a succeeding distributor). 

  
 -23- 

 Section 10.6 Reimbursement by Histogen. In the event that Histogen terminates
the LSA pursuant to Section 10.2(v) or (vii) above, then Histogen shall repay Pineworld for 60% of actual out of pocket Clinical Trial costs and Milestone Payments made to Histogen. Such repayment shall be
completed within five (5) years of the First Commercial Sale by Histogen or its Affiliate, licensee, agent or distributor of the Product following termination of this Agreement. 

ARTICLE 11 

INTELLECTUAL PROPERTY 

Section 11.1 Current and Future Intellectual Property. All current, existing as of the Effective Date, and future Intellectual
Property relating to any proprietary information of Histogen, the API, the Products and derivatives, improvements and modifications (collectively, “Improvements”) of each of the Products and any underlying Intellectual Property
(regardless of the Party responsible for such developments), shall be owned by (and as needed, assigned to) Histogen (“Histogen IP”), and shall be honored by Pineworld. 

Section 11.2 Intellectual Property Licenses to Pineworld. In addition to the licenses granted herein under this LSA, Histogen
hereby grants Pineworld a non-exclusive, non-assignable (other than (a) to Huapont Life Sciences Co., Ltd., (b) with Histogen’s prior written consent, or
(c) in the event of a Change of Control), non-sublicensable (except as set forth in Section 2.3), royalty free, fully paid license in the Territory, for the Term of the LSA, to
such Intellectual Property constituting Histogen IP that is an Improvement of the original Product IP underlying the Products, and was jointly developed by the Parties or developed by Pineworld, for the sole purpose of effecting its duties under the
LSA in the Territory, unless otherwise agreed in writing by the Parties (the “Histogen IP License”). 
 Section 11.3
Pineworld Intellectual Property. Any Intellectual Property and Improvements relating to the LSA, but excluding all Histogen IP, to the extent conceived, reduced to practice, developed or Controlled solely by Pineworld, shall be owned by
Pineworld (“Pineworld IP”), and shall be honored by Histogen. 
 Section 11.4 Jointly Held Intellectual
Property. Any Intellectual Property (i) not constituting Histogen IP or Pineworld IP and (ii) jointly developed by the Parties shall be jointly held by the Parties. 

Section 11.5 Intellectual Property Licenses to Histogen. Pineworld shall grant Histogen an exclusive, non-assignable (other than to Affiliates, who shall use the license for fulfillment of the purpose of the LSA), royalty free, fully paid up, worldwide license to practice any Pineworld IP developed in the course of
the Agreement that would be useful or beneficial in the manufacture, packaging or finalization of the Product or API, but only to the extent it is used in the manufacture, packaging, or finalization of the Product or API. Histogen may sublicense the
above license to its Affiliates, or other Third Parties pre-approved in writing by Pineworld, where Histogen shall at all times remain liable for the compliance with the terms of the LSA by any sublicensee,
and as a condition of any sublicense, such sublicensee shall undertake in writing to comply with the terms of the LSA. 

  
 -24- 

 Section 11.6 Intellectual Property Enforcement. 

(a) In the event that either Party becomes aware of any infringement or potential infringement of any of the Product IP by the manufacture,
use, distribution, marketing or sale of any Competing Products by a Third Party, such Party shall promptly notify the other Party in writing, identifying the infringer or potential infringer and the infringement complained of and furnishing the
information upon which such determination is based. Histogen shall have the right, but not the obligation, to sue such alleged infringers in the Territory. Histogen shall consult with Pineworld prior to initiating any such infringement suit in
the Territory to ensure that the intended course of action is not likely to adversely affect Pineworld’s Commercialization of the Product within the Territory. 

(b) Upon reasonable request by Histogen and at Histogen’s cost, Pineworld shall cooperate with Histogen and provide all reasonable
information and assistance including allowing Histogen access to Pineworld’s files and documents and access to Pineworld’s personnel and legal counsel who may have possession of relevant information, and if necessary to prosecute any legal
action, joining in the legal action as a party. 
 (c) Histogen shall bear the cost of any action or measures taken in accordance with this
Section 11.6 and any damages or remuneration received by Histogen as a result of such action or measures shall be Histogen’s exclusive property to which Pineworld will have no right, title, or interest. 

Section 11.7 Infringement of Third Party Intellectual Property. 

(a) In the event of any actual or threatened suit against Pineworld or its Affiliates, sublicensees or customers alleging that the import, sale
or use of the Product within the Territory and/or the exploitation or use of the Product IP or Histogen Trademarks hereunder infringes the Patent, Trademark or other Intellectual Property rights of a Third Party, Pineworld shall promptly give
written notice to Histogen and the defense and settlement of such suit shall be handled pursuant to Sections 9.2-9.3. Moreover, to the extent that Histogen has indemnity obligations under
Section 9.2, Pineworld will provide to Histogen all reasonable assistance requested by Histogen to defend or settle such suit and in particular Pineworld will promptly make available to Histogen, free of charge, all
information in its possession or control which will assist Histogen in defending or otherwise dealing with such suit. Histogen shall retain the ability to control, settle and otherwise resolve any infringement claims for which an indemnity
obligation under Section 9.2 exists. In addition to the rights and obligations of Histogen in Article 9, Histogen shall also retain the right to terminate its obligations under the LSA if it no
longer practicable in light of such Third Party claim or claims. Nothing in this Section or Sections 9.2 or 9.3 will require Histogen to indemnify or assume the defense of any infringement claim of a Third Party that
does not fall within its indemnity obligations of Section 9.2. 
 (b) If, in connection with any infringement
claim, Histogen consents to Pineworld entering into a Third Party license agreement for any Intellectual Property that is necessary to Commercialize the Products within the Territory, then Pineworld may offset Royalty Payments due hereunder by 50%
of the amounts due and actually paid under such Third Party license agreement; provided, that under no circumstance will the Royalty Payments due to Histogen be offset by more than 50% of the Royalty Payments otherwise owed to Histogen. 

  
 -25- 

 ARTICLE 12 

CONFIDENTIALITY 

Section 12.1 Confidential Information. As used in this Agreement, the term “Confidential Information” means all
information, whether it be written or oral, including all production schedules, lines of products, volumes of business, processes, new product developments, product designs, formulae, technical information, laboratory data, clinical data, patent
information, know-how, trade secrets, financial and strategic information, marketing and promotional information and data, and other material relating to any products, projects or processes of one Party (the
“Disclosing Party”) that is provided to, or otherwise obtained by, the other Party (the “Receiving Party”) in connection with this Agreement (including information exchanged prior to the date hereof in connection
with the transactions set forth in this Agreement). Notwithstanding the foregoing sentence, Confidential Information shall not include any information or materials that: 

(a) were already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by the Disclosing
Party, to the extent such Receiving Party has documentary evidence to that effect; 
 (b) were generally available to the public or otherwise
part of the public domain at the time of disclosure thereof to the Receiving Party; 
 (c) became generally available to the public or
otherwise part of the public domain after disclosure or development thereof, as the case may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement; 

(d) were disclosed to a Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing
Party not to disclose such information to others; or 
 (e) were independently discovered or developed by or on behalf of the Receiving Party
without the use of the Confidential Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect. 

Section 12.2 Confidentiality Obligations. During the Term and for seven (7) years thereafter, either Party shall keep all
Confidential Information received from or on behalf of the other Party with the same degree of care with which it maintains the confidentiality of its own Confidential Information, but in all cases no less than a reasonable degree of care. Neither
Party shall use such Confidential Information for any purpose other than in performance of this Agreement or disclose the same to any other person other than to such of its and its Affiliates’ directors, officers, managers, employees,
independent contractors (e.g., CRO, SMO, and investigational sites), agents, consultants or, solely with respect to Pineworld, its sublicensees who have a need to know such Confidential Information to implement the terms of this Agreement or enforce
its rights under this Agreement; provided, however, that a Receiving Party shall advise any of its and its Affiliates’ directors, officers, managers, employees, independent 

  
 -26- 

 
contractors (e.g., CRO, SMO, and investigational sites), agents, consultants or, solely with respect to Pineworld, its sublicensees, who receives such Confidential Information of the confidential
nature thereof and of the obligations contained in this Agreement relating thereto, and the Receiving Party shall ensure (including, in the case of a Third Party, by means of a written agreement with such Third Party having terms at least as
protective as those contained in this Article 12) that all such directors, officers, managers, employees, independent contractors (e.g., CRO, SMO, and investigational sites), agents, consultants or, solely with respect to
Pineworld, its sublicensees comply with such obligations. Upon termination of this Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in
the possession of the Receiving Party or its directors, officers, managers, employees, independent contractors (e.g., CRO, SMO, and investigational sites), agents, consultants or, solely with respect to Pineworld, its sublicensees, except that the
Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall be deemed to be the property of the Disclosing Party, and shall continue
to be subject to the provisions of this Article 12. It is understood that receipt of Confidential Information under this Agreement will not limit the Receiving Party from assigning its employees to any particular job or task in any way it may
choose, so long as such recipient shall have agreed in writing to maintain the confidentiality of Confidential Information in accordance with the terms of this Agreement. The Receiving Party shall remain responsible for any failure by any such
Person to treat such Confidential Information as required by this Agreement. If the Receiving Party is required to disclose Confidential Information in response to a court order or subpoena or to comply with the rules or regulations of regulatory
agency or governmental agency in any country, the Receiving Party shall provide prior notice of such intended disclosure to the Disclosing Party in sufficient time to enable the Disclosing Party to object or seek a limitation as to the scope of the
disclosure. 
 Section 12.3 Permitted Disclosure and Use. Notwithstanding Section 12.2, (i) either
Party may disclose Confidential Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) comply with or enforce any of the provisions of this Agreement; (b) comply with Applicable Laws;
(c) respond to subpoena or other compulsory legal process; or (d) disclose Confidential Information related to the Product only to the extent such disclosure is made to a governmental authority, including regulatory authority, and is
reasonably necessary to obtain or maintain Regulatory Approval of a Product, as applicable. If a Party deems it necessary to disclose Confidential Information of the other Party pursuant to this Section 12.3, such Party
shall give advance written notice of such disclosure to the other Party sufficient to permit such other Party reasonable opportunity to object to such disclosure or to take measures to ensure confidential treatment of such information, including
seeking a protective order or other appropriate remedy. 
 Section 12.4 Notification. The Receiving Party shall notify the
Disclosing Party promptly upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information, and will cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party
to regain possession of such Confidential Information and to prevent its further unauthorized use or disclosure. 

  
 -27- 

 ARTICLE 13 

MISCELLANEOUS 

Section 13.1 Taxes. Any taxes, duties, VAT or other assessments, including as payable on the sale of Product and its import from
the United States or customs clearance, shall be the responsibility of Pineworld. Each Party shall be liable for taxes in respect of its income. 

Section 13.2 Anti-Corruption Compliance. Each Party makes the following representations and warranties: 

(i) Compliance. Neither Party nor any of its Affiliates, nor any of their respective shareholders, directors, officers, employees,
agents, consultants or other representatives have performed or will perform, in connection with this Agreement, directly or indirectly, any act constituting a violation of the FCPA, or the anti-bribery laws of the Territory or any other countries,
or any regulations promulgated thereunder, including, without limitation, making, promising to make or offering to make any contribution, gift, bribe, rebate, payoff, influence payment, kickback or other payment to anyone, including any
“foreign official” (as defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, whether in money, property, services or anything else of value, in violation of any Laws or for
the purpose of (1) obtaining favorable treatment in securing business, (2) paying for favorable treatment for business secured, (3) obtaining special concessions or for special concessions already obtained, (4) otherwise
influencing the acts of such foreign official, political party or official thereof or candidate for foreign political office in their official capacity, or (5) otherwise obtaining an improper advantage in securing or retaining business. 

(ii) No Foreign Official Agents. No director, officer, employee, agent, consultant or other representative of either Party is a
“foreign official” (as defined in the FCPA). 
 (iii) Cooperation with Investigations. Each Party will fully cooperate with
any ethics or compliance investigations into possible FCPA violations of the FCPA or the anti-bribery laws and regulations of the Territory or other countries that arise in connection with this Agreement. 

(iv) Complete and Accurate Books and Records. Each Party will keep accurate financial books and records in connection with its
performance under this Agreement. 
 Section 13.3 Force Majeure. All cases of force majeure, i.e., any events beyond the
reasonable control of the Parties due to fire, flood, earthquake, explosion, riot, strike, lockout, war and similar casualties, shall, for the duration and to the extent caused by such disturbances, release the affected Party from the performance of
its obligations hereunder (except Pineworld’s payment obligations hereunder). Either Party shall notify the other Party promptly in the event of any indications of any such incidents occurring and shall discuss the effect of such incidents
on this Agreement and the measures to be taken. Either Party shall use its best endeavors to reasonably avoid or restrict any detrimental effects in connection with such incidents. 

  
 -28- 

 Section 13.4 Non-Solicitation. The
Parties will not, directly or indirectly, either alone or in association with any other person or entity, cause or attempt to cause any employee, agent or contractor of the other Party or any Affiliate thereof to terminate their employment, agency
or contractor relationship with the other Party or any Affiliate thereof (provided, however, that the foregoing does not prohibit initiating employee searches through the use of general advertisement in the media (including
trade media or internet postings) or through the engagement of firms to conduct employee searches that are not targeted or focused on employees, agents or contractors of the other Party or any Affiliate thereof), during the Term and for twenty four
(24) months thereafter. 
 Section 13.5 Publicity. Neither Party shall make a public announcement regarding the fact of
conclusion of this Agreement without the prior written consent of the other Party. When one Party wishes to make a public announcement regarding the Agreement, such Party shall notify the other Party of its intended announcement text and other
relevant information on which the other Party may comment. 
 Section 13.6 Assignment. The LSA shall not be assignable by either
Party (other than as described herein) without the prior written consent of the other Party, except that (i) Pineworld may make an assignment, in whole or in part, to Huapont Life Sciences Co., Ltd. without Histogen’s consent; and
(ii) either Party may make an assignment, in whole or in part, without the other Party’s consent in the event of a Change of Control. Any permitted assignment shall be binding on the successors of the assigning Party. 

Section 13.7 Severability. If any provision of this Agreement is held invalid, illegal or unenforceable, the remaining provisions
of this Agreement remain in full force and effect, if the essential terms and conditions of this Agreement for each party remain valid, binding and enforceable. 

Section 13.8 Interpretation. In the negotiation of this LSA, each Party has received advice from its own attorney. The language
used in this LSA is the language chosen by the Parties to express their mutual intent, and no provision of this LSA will be interpreted for or against either Party because that Party or its attorney drafted the provision. The headings of each
ARTICLE and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular ARTICLE or Section. 

Section 13.9 Survival. All provisions in Section 3.3, and Articles 1, 5, 7, 9 10, 11, 12 and
13 shall survive the termination, cancellation or expiration of this LSA. 
 Section 13.10 Dispute Resolution. The
Parties hereto shall use their best efforts to settle amicably any controversies arising out of this Agreement. Any controversy or disputes or claims arising between the Parties in connection with this Agreement which cannot be settled in an
amicable way shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (the “ICC Rules”), by a single arbitrator agreed by the Parties or, in the absence of agreement, appointed in accordance
with the ICC Rules. Any award or decision made in such arbitration shall be final and binding upon the Parties and enforceable in a court of competent jurisdiction. The arbitration shall be held in Singapore. 

  
 -29- 

 Section 13.11 Jurisdiction. Without derogating from the agreement to arbitration
aforesaid, exclusive jurisdiction for disputes and all proceedings shall be in the competent courts of Singapore. 
 Section 13.12
Governing Law. Governing law shall be California law, without regard to conflict of laws provisions that would require the application of the laws of any other jurisdiction, and the application of United Nations Convention on Contracts for
the International Sale of Goods is expressly excluded. 
 Section 13.13 Entire Agreement; Amendment. This LSA, including the
exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and
supersedes, as of the Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof (including the Term Sheet). There are no covenants, promises, agreements, warranties, representations,
conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this LSA shall be binding upon the Parties unless reduced to writing
and signed by an authorized representative of each Party. 
 Section 13.14 Waiver. No waiver by any party of any of the
provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power or privilege
arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other
right, remedy, power or privilege. 
 Section 13.15 Third Party Beneficiaries. This Agreement is entered into for the sole
protection and benefit of the Parties, and their respective permitted successors and assigns. No other person shall have any rights or causes of action under this Agreement. 

Section 13.16 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically
refer to this LSA, and shall be addressed to the appropriate Party at the address specified below, and shall be deemed to have been given for all purposes (i) when delivered, if hand-delivered or sent by facsimile on a business day,
(ii) on the third (3rd) business day after mailing if sent by a reputable international overnight courier service, or (iii) on the seventh
(7th) business day after mailing, if mailed by first-class certified or registered airmail, postage prepaid, return receipt requested. Unless otherwise specified in writing, the mailing addresses
of the Parties shall be as described below: 
 If to Histogen: 

Histogen Inc. 
 10655 Sorrento
Valley Road 
 San Diego, CA 92121 

Attn: Dr. Gail Naughton 

  
 -30- 

 If to Pineworld: 

No. 69 Xingguang Ave, 
 Yubei
District, 401121, Chongqing 
 Attn: Yizhuo Zhang 

Facsimile: 
 Section 13.17
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

[Signature page follows] 

  
 -31- 

 IN WITNESS WHEREOF, the Parties have
executed this LSA by their duly authorized representatives as of the Effective Date. 
  

			
	HISTOGEN, INC.
		
	By:	 	 /s/ Gail K. Naughton

		 	Name: Gail K. Naughton
		 	Title: CEO & Chairman
	
	PINEWORLD CAPITAL LIMITED
		
	By:	 	 /s/ Yizhuo Zhang

		 	Name: Yizhuo Zhang
		 	Title: Chairman

  
 Signature page to
Exclusive License and Supply Agreement 

 Exhibit 1: Schedule of Patents and Trademarks 

 

																	
	 Reference #
	 	 Title
	 	 CNTRY
	  	 Serial #
	  	 Filed Date
	  	 Patent #
	  	 Issue Date
	  	 Status
	  	 Expiration

	HIST1120/CN/3	 	Extracellular Matrix Compositions	 	CN	  	200980110464.5	  	01/30/2009	  		  		  	PUBLISHED	  	01/30/2029
									
	HIST1120/CN/7	 	Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic Conditions	 	CN	  	201080040131.2	  	07/09/2010	  		  		  	PUBLISHED	  	07/09/2030
									
	HIST1120/MX/7	 	Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic Conditions	 	MX	  	MX/a/2012/000455	  	07/09/2010	  		  		  	PUBLISHED	  	07/09/2030

 The trademark “Histogen”. 

  
 -1- 

 Exhibit 2: Pharmacovigilance Agreement 

PHARMACOVIGILANCE 

AGREEMENT 
 This Agreement
is made this [___] day of [______________, ______], by and between Histogen, Inc., a corporation organized under the laws of the State of Delaware, with a principal place of business at ___________________________________
(“HISTOGEN”) and Pineworld Capital Limited, a limited liability company organized under the laws of China, with a principal place of business at ______________________________________ (“PINEWORLD”). 

WHEREAS HISTOGEN and PINEWORLD have entered into a certain Exclusive License and Supply Agreement dated _________ (the “LSA”) under
which PINEWORLD will distribute a certain Product(s) manufactured and supplied by HISTOGEN and will conduct clinical studies of the Product(s) in China; and 

WHEREAS the parties wish to set forth the procedures and responsibilities for reporting of adverse events relating to the Product(s), to
ensure compliance with all applicable legal and regulatory requirements. 
 NOW, THEREFORE, the parties, intending to be bound, agree as
follows: 
 1. DEFINITIONS 

The following definitions of terms apply to this Agreement: 

(a) Adverse Drug Experience. Any adverse event associated with the use of a drug in humans, whether or not considered drug related,
including the following: An adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose whether accidental or intentional; an adverse event occurring from drug abuse; an
adverse event occurring from drug withdrawal; any failure of expected pharmacological action; a Medication Error; or Other Reportable Information. 

(b) Date of First Receipt (DFR). The calendar date when the first employee of PINEWORLD is notified of an Adverse Drug Experience. 

(c) Disability. A substantial disruption of a person’s ability to conduct normal life functions. 

(d) Life-threatening adverse drug experience. Any Adverse Drug Experience that places the patient, in the view of the initial reporter,
at immediate risk of death from the adverse drug experience as it occurred, i.e., it does not include an adverse drug experience that, had it occurred in a more severe form, might have caused death. 

(e) Product(s). HISTOGEN’s Product(s) injectable Hair Stimulating Complex. 

(f) Serious Adverse Drug Experience. Any Adverse Drug Experience occurring at any dose that results in any of the following outcomes:
Death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not
result in death, be life-threatening, or require hospitalization may be considered a Serious Adverse Drug Experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical
intervention to prevent one of the outcomes listed in this definition. 
 (g) Unexpected Adverse Drug Experience. Any adverse drug
experience that is not listed in the current labeling for the drug product. This includes events that may be symptomatically and pathophysiologically related to an event listed in the labeling, but differ from the event because of greater severity
or specificity. 

  
 -1- 

 (h) Medication error. Any preventable event that may cause or lead to inappropriate
medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. 
 (i) Other
Reportable Information: Any drug exposure during pregnancy; lactation exposure; drug misuse; off-label use; drug interaction; drug intolerance; unintended occupational exposure; suspected transmission of
infectious agents regardless of whether the product was used on of off-label; and any unexpected therapeutic or clinical benefit. 

2. PINEWORLD RESPONSIBILITIES 

(a) Procedure: PINEWORLD shall have in place standard operating procedures with regard to the collection and reporting of Adverse Drug
Experiences that comply with the terms of this Agreement and all regulatory requirements including 21 C.F.R. § 312.32, 21 C.F.R. § 314.81 and those prescribed by the CFDA for marketed products and those under an IND. PINEWORLD shall
provide HISTOGEN with a copy of all such procedures upon written request from HISTOGEN. 
 (b) Information to be Reported: PINEWORLD
shall report all Adverse Drug Experiences, Medication Errors and Other Reportable Information relating to the Product(s) to HISTOGEN per the requirements set forth below. PINEWORLD shall forward to HISTOGEN only those Adverse Drug Experiences for
which the HISTOGEN product is named as suspect in the Adverse Drug Experience report. Each such report shall contain all of the information known to PINEWORLD relating to the Adverse Drug Experience, but, at a minimum, shall contain: 

(i) an identifiable patent; 

(ii) an identifiable reporter; 

(iii) a suspected product; and 

(iv) an adverse event, medication error, other reportable information or fatal outcome. 

These terms shall be interpreted in accordance with FDA’s GUIDANCE FOR INDUSTRY: POSTMARKETING ADVERSE EXPERIENCE REPORTING FOR HUMAN DRUG AND LICENSED
BIOLOGICAL PRODUCTS, August 1997. PINEWORLD will use its best efforts to collect all of the information relating to the Adverse Drug Experience, including the lot number and product code for the suspected product, before reporting it to HISTOGEN.
PINEWORLD shall not report any event to HISTOGEN without all of items (i)-(iv) above. 
 (c) Information provided to HISTOGEN: All
reports, initial and follow up, will be provided as they are received at PINEWORLD (original source documents). 
 (d) Transfer of
information to HISTOGEN: All source documents regarding adverse event information shall be submitted in English as a secure PDF in an email and sent to ______________________, or, in the alternative, by facsimile to the attention of
PHARMACOVIGILANCE DEPARTMENT at ____________________. 
 (e) Time Deadlines for Reporting: PINEWORLD shall submit initial reports on
Adverse Drug Experiences within two (2) business days of obtaining information about the Adverse Drug Experience sufficient to make it reportable to HISTOGEN under subsection 2(b). Initial reports may be submitted by PINEWORLD via source
documents, with a follow-up Form FDA 3500A form provided by PINEWORLD within ten (10) days of obtaining information about the Adverse Drug Experience sufficient to make it reportable to HISTOGEN under
subsection 2(b). 

  
 -2- 

 (f) Cooperation: PINEWORLD shall cooperate with HISTOGEN with regard to all Adverse
Drug Experience reporting requirements and shall respond in a timely manner to any inquiries made by HISTOGEN. PINEWORLD shall cooperate with HISTOGEN in obtaining additional information as may be necessary after PINEWORLD’s submission to
HISTOGEN of any initial report. 
 (g) Reconciliation: PINEWORLD shall cooperate with HISTOGEN in conducting a reconciliation of all
ADE reports. Such reconciliation shall take place every six (6) months during the months of ____________ and ________________. 
 3.
HISTOGEN AND JOINT RESPONSIBILITIES 
 (a) Reporting: HISTOGEN shall be solely responsible for submission of all adverse drug
experience reports to the U.S. Food and Drug Administration about the Product(s) on a timely basis. HISTOGEN shall comply with all requirements of 21 C.F.R. § 312.33, 21 C.F.R. § 314.80, and all other applicable laws and requirements.
HISTOGEN will provide PINEWORLD of confirmation of receipt of any report of any adverse drug experience. HISTOGEN will report all serious unexpected adverse drug experience reports received from PINEWORLD to FDA within fifteen (15) days of Date
of First Receipt from PINEWORLD. PINEWORLD shall be solely responsible for submission of all adverse drug experience reports to the China Food and Drug Administration about the Product(s) on a timely basis. PINEWORLD shall comply with all CFDA
reporting requirements, and provide HISTOGEN copies of any such correspondence upon request. 
 (b) Safety Database: HISTOGEN shall be
solely responsible for maintenance of all required safety databases with regard to the Product(s), and will prepare and submit all Annual IND safety reports, Periodic Adverse Experience Reports and Periodic Safety Update Reports as may be required.

 (c) Notifications: Each party, through its Regulatory Affairs contact, will notify the other party, through its Regulatory Affairs
contact, of any significant findings relating to adverse drug experience reported to it which may affect the safety and effectiveness profile of the Product(s), including any suspension of clinical studies for safety reasons by an Ethics Committee
or Regulatory Authorities. Each party, through its Regulatory Affairs contact, will notify the other party, through its Regulatory Affairs contact, of any inquiries from the Food and Drug Administration, China Food and Drug Administration or any
other regulatory authority relating to the adverse drug experiences reported by the party on the Product(s) within two (2) business days. 

4. AUDITS AND INSPECTIONS: 

(a) Audits: No more than one per calendar year of this Agreement, HISTOGEN will have the right to conduct an audit of PINEWORLD’S
records at PINEWORLD’s facility to evaluate compliance with this Agreement and with applicable laws and regulations. Any such audit will be conducted during PINEWORLD’s normal business hours and shall in no event last more than two
(2) business days. HISTOGEN, through its Quality Assurance contact, shall provide PINEWORLD, through its Quality Assurance contact, at least thirty (30) days written notice of any request to audit PINEWORLD. PINEWORLD shall make itself
available in a reasonable time based on HISTOGEN’S request. 

  
 -3- 

 (b) Inspection: If either party is audited by the Food and Drug Administration, the
China Food and Drug Administration or any other regulatory authority, with regard to pharmacovigilance issues relating to the HISTOGEN products, the party being inspected shall, through its Regulatory Affairs contact, advise the Regulatory Affairs
contact of other party when it learns of the inspection. 
 Each party will provide the other with findings of the inspection, corrective
and preventive actions taken as a result of the inspection, and monthly progress reports until completed and as it pertains to the HISTOGEN product. 

5. CONTACTS: 
 (a) For
HISTOGEN: 
  

									
	Pharmacovigilance Issues	  		  	Regulatory Issues
	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

	Phone:	 	
                     

	  		  	Phone:	  	
                     

	Fax:	 	  
	  		  	Fax:	  	  

	E-mail:	 	  
	  		  	Email:	  	  

 

									
	Quality Assurance	  		  	
	  
	  		  	
	  
	  		  	
	  
	  		  	
	Phone:	 	
                 
	  		  		  	
	Fax:	 	  
	  		  		  	
	E-mail:	 	  
	  		  		  	

 (b) For PINEWORLD: 

 

									
	Pharmacovigilance Issues	  		  	Regulatory Issues
	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

	Phone:	 	
                     

	  		  	Phone:	  	
                     
            

	Fax:	 	  
	  		  	Fax:	  	  

	E-mail:	 	  
	  		  	Email:	  	  

 

									
	Quality Assurance	  		  	
	  
	  		  	
	  
	  		  	
	  
	  		  	
	Phone:	 	
                     

	  		  		  	
	Fax:	 	  
	  		  		  	
	E-mail:	 	  
	  		  		  	

  
 -4- 

 6. TERM/SURVIVAL: 

(a) Term: This Agreement shall be in effect during the term of the LSA. 

(b) Survival: Notwithstanding the termination of this Agreement, PINEWORLD shall report to HISTOGEN any Adverse Drug Experiences it
receives following termination of this Agreement as set forth in Article 2. 
 7. CONFIDENTIALITY/PRIVACY 

(a) Confidentiality: All information exchanged between the parties pursuant to this Agreement shall be treated as confidential pursuant
to the terms of the LSA. 
 (b) Privacy: The parties agree in performing their duties and responsibilities under this Agreement that
they shall comply with all U.S. federal and state laws relating to the protection of personally identifiable health information relating to the Adverse Drug Experiences collected and reported hereunder, and any laws or regulations in China relating
thereto. 
 8. COUNTERPARTS 

This Agreement shall become binding when any one or more counterparts hereof whether received in original or by PDF, individually or taken
together, shall bear the signatures of each of the parties. This Agreement may be executed in any number of counterparts, each of which shall be deemed binding on the party on whose behalf it was executed, but all of which taken together shall
constitute but one and the same instrument. 
 * * * * 

Executed and made effective on the date set forth hereinabove by and between: 

 

									
	HISTOGEN, INC.	 		  	PINEWORLD CAPITAL LIMITED
					
	By	 	  
	 		  	By	  	
                     

		 	Name:	 		  	Name:	  	  

		 	Title:	 		  	Title:	  	  

  
 -5-EX-10.60

 Exhibit 10.60 

Confidential 
 [*] Certain information in
this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. 

AMENDED AND RESTATED LICENSE AGREEMENT 

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of
December 16, 2013 (the “Amendment Effective Date”) by and between Histogen, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 10655 Sorrento Valley Road, San Diego,
California 92121 (“Histogen”) and Suneva Medical, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 5870 Pacific Center Boulevard, San Diego, California 92121
(“Suneva”). 
 WHEREAS, Suneva and Histogen previously entered into that certain License Agreement dated as of
February 3, 2012 (the “Original Agreement”), and the parties wish to amend and restate the Original Agreement in its entirety, maintaining, except as otherwise expressly stated, the original February 3, 2012
“Effective Date”); 
 WHEREAS, Histogen is the sole owner of, or has licensed in, the Licensed Intellectual Property
(as defined below); 
 WHEREAS, Histogen is the developer and owner of the ReGenicaTM line of topical skin care products; 

WHEREAS, Histogen and Suneva, as a condition to entering into this Agreement, are also entering into an Amended and Restated Supply
Agreement dated as of the date hereof (the “Supply Agreement”); and 
 WHEREAS, Suneva desires to obtain, and
Histogen wishes to grant to Suneva, an exclusive, royalty-bearing license to the Licensed Intellectual Property, ReGenica Products, and certain future products to be developed in the Field of Use and in the Territory ( each as defined below),
subject to and in accordance with the terms and conditions of this Agreement. 
 NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by the parties, and intending to be legally bound, the parties agree as follows: 

ARTICLE 1 
 Definitions

 For the purposes of this Agreement, the following capitalized words and phrases shall have the following meanings: 

1.1 “Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended to date and as may be further
amended from time to time during the Term (as defined below), and the regulations promulgated with respect thereto. 

  
 -1- 

 Confidential 

 

 1.2 “Affiliate” means, with respect to any Person, any other Person
which directly or indirectly controls, is controlled by, or is under common control with, such Person, only for so long as such control continues to exist. A Person shall be regarded as in control of another Person if it owns, or directly or
indirectly controls, at least fifty percent ( 50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other
Person by any means whatsoever. 
 1.3 “Applicable Law” means all laws, rules, regulations and guidelines within the
Territory (including, but not limited to, the Act and all regulations promulgated thereunder), as existing as of the Effective Date and as may be amended from time to time thereafter, that apply to the import, export, research and development,
manufacture, marketing, distribution and/or sale of Products in the Territory or the performance of either party’s obligations under this Agreement, in each case to the extent applicable and relevant to such party. 

1.4 “Encumbrance” means any lien, license, security interest, pledge, option or other encumbrance, restriction or
limitation of any kind whatsoever that would (if ever enforced or exercised) prevent Suneva from ( or otherwise adversely impact Suneva in) fully exercising or otherwise exploiting the rights granted under Section 2.1 and elsewhere in this
Agreement. 
 1.5 “CCM” or “Cell Conditioned Media” means any tissue culture media conditioned by
newborn fibroblast cells that when grown under simulated embryonic conditions, become multipotent stem cells, however created, developed, manufactured or otherwise utilized by Histogen or its Affiliates. 

1.6 “Change of Control” means a change in the ownership of Histogen ( as defined by either the acquisition or control
of a majority interest in the equity of Histogen or control of a majority of the Histogen Board of Directors by any company manufacturing or marketing medical aesthetics products or in connection with an initial public offering by Histogen or a
reverse merger transaction pursuant to which Histogen becomes a public reporting company) or a change in the ownership or control of the Licensed Intellectual Property or Products; but excluding however, any Control that might be acquired by
Lordship Ventures, LLC (or its Affiliates) or any other equity owner of Histogen, in which case, said equity owner shall have the same rights and responsibilities with respect to this License Agreement and the Supply Agreement as Histogen. 

1.7 “Control” means with respect to any item of or right under any Patents, Technical Information, or Trademarks or any
other Intellectual Property Rights, the possession of (whether by ownership or license, other than pursuant to this Agreement) or the ability of a party or, if applicable, any of its Affiliates to grant a license or sublicense of such items or right
as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such party would be required hereunder to grant the other party such license or sublicense and without payment of
additional consideration to such Third Party. 

  
 -2- 

 Confidential 

 

 1.8 “Cover” or “Covering” means, (i) with
respect to a Patent, that at least one Valid Claim of such Patent would be infringed by the product, method, use, or device, as applicable, and (ii) with respect to any other Intellectual Property Right, that the product, method, use or device
would infringe or misappropriate such rights unless a license were granted. 
 1.9 “FDA” means the United States Food
and Drug Administration and any successor entity thereto. 
 1.10 “Field of Use” means Products used to address any
symptom or condition, including without limitation, the signs, symptoms and appearance of aging skin, as dispensed, directly or indirectly, by a physician from the physician’s office, clinic, hospital, medical spa or website. Only medical spa
or website accounts with an associated medical license number will be within the Field of Use. 
 1.11 “Finished
Product” means a saleable Product in final trade dress and packaging. 
 1.12 “First Commercial Sale” shall
mean the first sale by Suneva, or its Affiliates or Sublicensees, of a Product for use or consumption by the general public. Sales for test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar uses shall not
be considered to constitute a First Commercial Sale. 
 1.13 “GAAP” means U.S. generally accepted accounting
principles as in effect at the relevant time or for the relevant period applied on a consistent basis during the period involved. 
 1.14
“Competition” means, on a Product-by-Product basis, the commercial launch of a Similar Product in the Territory after the Effective Date. It shall
be Suneva’s burden to establish by a preponderance of the evidence that Competition exists. Non-limiting examples of objective evidence by which Suneva may demonstrate the existence of Competition include
websites, advertisements, point of sale displays, and exhibits at tradeshows. 
 1.15 “ReGenica Products” means
current topical products from Histogen’s ReGenica product line, including “Day”, “Overnight” and “Post-Resurfacing” products, along with any future topical products developed, manufactured or sold by Histogen that
contain or utilize CCM for skin care and facial cosmetic applications. Histogen represents that the ReGenica Products (as finished goods and if properly handled and stored per Histogen’s instructions) have a twenty-four (24) month shelf
life. 
 1.16 “Similar Product” means any product, other than a Product introduced by Suneva or its Affiliates, that
contains CCM or similar technology as an ingredient that is marketed in the Field of Use and does not require approval or clearance by Regulatory Authority prior to sale. 

  
 -3- 

 Confidential 

 

 1.17 “Improvements” means any adaptation, change, redesign,
modification, invention, discovery, enhancement or development conceived, reduced to practice, developed or made after the Effective Date and (i) incorporated into a Product, (ii) made with respect to the specifications, the raw materials
or the method or process of manufacture or production of a Product, including, but not limited to, any product which uses CCM or similar technology and performs the same function as a Product, (iii) incorporating, utilizing, or developed
utilizing, Technical Information to create a Similar Product, (iv) requiring the practice of an invention claimed in the Patent Rights to create a Similar Product, or (v) serves to create a Similar Product. 

1.18 “Intellectual Property Rights” means any and all patent rights, copyright rights, trade secret rights, sui
generis database rights and all other intellectual and industrial property rights of any sort throughout the world (including, but not limited to, any application therefore) whether now known or hereafter existing. 

1.19 “Joint Improvement” means an Improvement with respect to which employees and/or agents of both Histogen and Suneva
are joint inventors in the course of performing any of their respective activities under this Agreement or under the Supply Agreement, regardless of whether any Third Parties are also joint inventors, including, without limitation, all Intellectual
Property Rights therein. Inventorship for Joint Improvements shall be determined in accordance with the patent laws of the United States (Title 35, United States Code). 

1.20 “Joint Patent” means any Patent Covering a Joint Improvement. 

1.21 “Licensed Intellectual Property” means, collectively: (i) the Patent Rights, (ii) the Technical
Information, (iii) Histogen Improvements and (iv) Histogen’s interest in any Joint Improvements and Joint Patents. 
 1.22
“Net Sales” means the gross amounts invoiced by Suneva or any Sublicensee for sales of Products to Third Parties (“Customers”), less the following deductions determined in accordance with GAAP, as consistently applied
by Suneva (and not recovered or reimbursed to Suneva or any of its Sublicensees) relating to such Product sales: 
  

	 	(a)	 trade (including to physician practices), cash and quantity discounts, allowances and credits;

  

	 	(b)	 credits, price adjustments and/or allowances for damaged products, product returns and/or rejections of
products; 

  

	 	(c)	 chargeback payments, fees, rebates ( or the equivalent thereof), price protection and shelf stock adjustments;
reprocurement charges and other similar charges; inventory management fees paid or granted to physician practices, group purchasing organizations, managed health care organizations, wholesalers, pharmaceutical benefits managers or other similar
organizations or to federal, state/provincial, local and other governments, including their agencies (including, but not limited to, any payments required by law to be made under Medicaid, Medicare or other government medical assistance programs),
or to trade customers; 

  
 -4- 

 Confidential 

 

	 	(d)	 reasonable outbound transportation prepaid or allowed and reasonable transportation insurance; and

  

	 	(e)	 sales, value-added, and excise taxes, tariffs and duties, and other taxes and other governmental charges
related to sale, importation or exportation (but not including taxes assessed against the income derived from such sale). 

Notwithstanding anything to the contrary, the transfer of a Product shall not be considered a sale of a Product under this Agreement to the extent such
transfer is for only nominal consideration and (i) is solely in connection with the research, development or testing of a Product, or (ii) is for sample purposes. It is understood that the majority of samples are to be packaged in volumes
of 5mL or less. However, it is also acknowledged that a reasonable quantity of full sized samples is needed for display and promotional purposes. For the sake of clarity, in the case of a sale, lease, license or other conveyance
(“Transfer”) of a Product within Suneva or between or among Suneva, its Affiliates or any of its other Sublicensees, solely for further transfer by such transferee to a Customer, Net Sales shall be based on the further Transfer of
such Product by such transferee to any such Customer. 
 Notwithstanding the foregoing, and solely for the purpose of calculating Royalties pursuant to
Section 6.2 below, Net Sales shall not be less than $60 per 1.5oz unit of the ReGenica Day and Overnight Products, respectively, and 1.0oz of the ReGenica Post-Resurfacing Product. 

1.23 “Patent” means any patent or patent application, including, without limitation, any United States provisional
application, any United States non-provisional application, and any continuation, continuation-in-part, divisional, registration,
confirmation, revalidation, reissue, substitution, reexamination, renewal, PCT application, patent term extension, SPC, and utility model, as well as all related extensions or restorations of terms thereof. 

1.24 “Patent Rights” means: (i) all Patents set forth on Schedule A; (ii) any other Patents (excluding the
Joint Patents), whether existing as of the Effective Date or arising thereafter, that at any time during the Term are owned or otherwise Controlled by Histogen and that have at least one Valid Claim Covering the composition of matter, method,
manufacture, formulation, sale or use of any Product in the Field of Use in the Territory; and (iii) any and all Patents and other rights issuing from, or filed subsequent to the Effective Date of this Agreement and based on or claiming
priority to or from, any of the Patents described in the preceding clause (i) of this definition, including, but not limited to, any Patents resulting from any of the foregoing. 

1.25 “Person” means an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint venture, non-profit organization, pool, syndicate, sole proprietorship, unincorporated organization, university, governmental authority or any other form of entity not specifically listed
herein. 
 1.26 “Histogen Improvement” means any Improvement with respect to which employees, agents and/or
subcontractors of Histogen are sole inventors in the course of performing any of the activities under this Agreement or under the Supply Agreement, including, without limitation, all Intellectual Property Rights therein. Inventorship for Histogen
Improvements shall be determined in accordance with the patent laws of the United States (Title 35, United States Code). 

  
 -5- 

 Confidential 

 

 1.27 “Product” means any topical formulation utilizing CCM or similar
technology developed by Histogen as an ingredient. For clarity, “Product” includes the ReGenica Products, including any and all Improvements, formulations, strengths and dosages thereof, and (i) any formulation of any topical product
which contains CCM or similar technology even if in combination with any other ingredient or (ii) any other product developed by Histogen for the Field of Use. “Product” does not include any Regulated Product (as defined in
Section 2.4). 
 1.28 “Regulatory Authority” means any administrative agency responsible
for the regulation of cosmetic or pharmaceutical products intended for human use, including, but not limited to, the FDA, and any other applicable administrative agency in the Territory having the aforementioned responsibilities and any successor
entities thereto. 
 1.29 “Regulatory Filings and Approvals” means any and all permits, licenses, approvals,
designations and authorizations required by any Regulatory Authority as a prerequisite to the development, manufacturing, packaging, marketing, selling and/or use of a Product in the Field of Use in any jurisdiction in the Territory, or otherwise
issued by any Regulatory Authority with respect to any Product in the Field of Use in any jurisdiction in the Territory, as well as any applications for any of the foregoing filed with any Regulatory Authority. 

1.30 “Royalty Term” means, with respect to each Product, a period starting on the date of the First Commercial Sale of
such Product in the Territory and expiring upon the last sale of any such Product by Suneva, or its Affiliates or Sublicensees, as authorized by this Agreement. 

1.31 “Sublicensee” means any Third Party or Affiliate of Suneva that has entered into an agreement with Suneva
sublicensing to such Third Party or Affiliate pursuant to Section 2.2 any of the rights granted to Suneva by Histogen pursuant to Section 2.1. For clarity, “Sub licensee” includes, but is
not limited to, any Third Party that is sublicensed or otherwise authorized by Suneva to import, export, offer for sale, sell or otherwise promote, market and distribute Products in the Territory, but which has no right to make or have made any
Products, such as distributors or value added resellers. 
 1.32 “Technical Information” means (i) any
technical, scientific and other data, information and know-how (including, but not limited to, any biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, and further including, but not limited to, study designs and protocols, assays and biological methodology) that (a) is
described on Schedule B, (b) was or is used, created or developed either by or on behalf of Histogen, and relates directly to a Product in the Field of Use or (c) is at any time during the Term owned or otherwise Controlled by
Histogen, whether existing as of the Effective Date or arising thereafter, and is necessary for the development, use or manufacture of Products for the Field of Use and (ii) any and all Intellectual Property Rights embodied in

  
 -6- 

 Confidential 

 

 
or associated with any of the foregoing; provided, however, that notwithstanding anything to the contrary, the Technical Information shall not include any Joint Patents or Joint Improvements nor
shall it include certain Histogen core technical information necessary to manufacture CCM (“CCM Technical Information”). 
 1.33
“Territory” means all countries and jurisdictions throughout the world with the exception of South Korea, China ( excluding Hong Kong, S.A.R.) and India. 

1.34 “Third Party” mean any Person other than Histogen, Suneva and their respective Affiliates. 

1.35 “Trademark” means any rights to: (i) the REGENICA trademark; (ii) any and all trademarks, service marks,
trade names, logos and trade dress specific to or typically used by Histogen with the REGENICA trademark or with any ReGenica Products; and (iii) any and all applications, registrations, common law rights and other rights with respect to any of
the foregoing. 
 1.36 “Suneva Improvement” means any Improvement with respect to which employees, agents and/or
subcontractors of Suneva are sole inventors in the course of performing any of the activities under this Agreement including, without limitation, all Intellectual Prope1ty Rights therein. Inventorship for Suneva Improvements shall be determined in
accordance with the patent laws of the United States (Title 35, United States Code). 
 1.37 “Valid Claim” means a
claim pending (and not abandoned by Histogen) in a Patent application included within the Patent Rights, or an issued and unexpired claim in a Patent included within the Patent Rights, which claim, in each case (i) has not been revoked or held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which claim has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise and (ii) would but for the license granted hereunder, be infringed by the
manufacturing, use, import, export, development, distribution, marketing, promotion, offer to sell and sale of a Product in the Field of Use in the Territory. 

ARTICLE 2 
 License Grant

 2.1 Grant of License 

2.1.1 License Grant 
 During the Term and subject
to Suneva’s compliance with the terms and conditions of this Agreement, Histogen, on behalf of itself and its Affiliates, hereby grants to Suneva an exclusive (even as to Histogen and its Affiliates), royalty-bearing, transferable (to the
extent permitted under Section 15.2 below) license, with the right to grant sublicenses in accordance with Section 2.2, under the Licensed Intellectual Property, solely in the Field of Use and
within the Territory and 

  
 -7- 

 Confidential 

 

 
solely to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise commercially exploit the Product throughout the
Territory. In the event of a Triggering Event (as defined in the Supply Agreement), Histogen, on behalf of itself and its Affiliates without any further action or requirement, shall grant to Suneva a
non-exclusive, transferable (to the extent permitted under Section 15.2 below) license, with the right to grant sublicenses in accordance with Section 2.2,
under the CCM Technical Information, solely in the Field of Use and within the Territory and solely to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise commercially
exploit the Product throughout the Territory. 
 2.1.2 Manufacture 

Notwithstanding the foregoing license to make and have made, Suneva shall not manufacture, make or have made the CCM ingredient for the Products other than in
accordance with the Supply Agreement. 
 2.1.3 Reserved Right 

Notwithstanding the foregoing exclusive license grant, Histogen reserves and retains the right to perform directly or indirectly, any and all research and
development activities concerning CCM and Products as Histogen deems appropriate. Further, the exclusivity described above in Section bl shall not preclude Histogen from performing its obligations under the Supply Agreement. Additionally, Histogen
retains the right to sell CCM to a Third Party for the medical spa market to be dispensed solely in a concentration of up to one-tenth of the CCM concentration for the Products through equipment that delivers
a multi-step dermabrasion-like therapy. Under no circumstances will Histogen or a Third Party use the ReGenica trademark or make any reference or comparison to the ReGenica Products. Additionally, Histogen will not sell or license CCM or any
permitted product to a Third Party unless the Third Party agrees to these restrictions and Suneva is named as a third party beneficiary to such agreement. Likewise, under no circumstances will Suneva use the trademark of, or make any reference or
comparison to, non-regulated cosmetic products developed and marketed by other Histogen partners. 
 2.1.4 Trademark Assignment 

Histogen hereby assigns and transfers all worldwide rights, title and interests in the Trademark to Suneva and agrees to execute all documents provided by
Suneva to effect such assignment and transfer, including any documents required to remove any liens or encumbrances on the Trademark. Histogen solely owns, and has at all times maintained sole ownership of, all right, title, and interest in and to
the Trademark, including the exclusive, absolute, irrevocable right, title and interest thereto, free and clear of any encumbrances. To the knowledge of the Histogen Parties, the Trademark does not infringe, or misappropriate any copyright,
trademark, service mark, trade secret or other Intellectual Property Right of any Third Party. To the knowledge of the Histogen Parties, the Trademark is and shall be valid and enforceable. To the knowledge of the Histogen Parties, there has not
been and is not currently any infringement, misappropriation or unauthorized use by any Third Party of the Trademark. 

  
 -8- 

 Confidential 

 

 2.2 Sublicensing 

Suneva shall have the right to sub license any of the rights granted in Section 2.1 to one or more of its Affiliates and/or Third
Pa1iies only upon obtaining Histogen’s prior written consent, which consent will not be withheld unreasonably; provided, however, that Suneva shall secure all appropriate covenants, obligations and rights from any permitted Sublicensee,
including, but not limited to, licenses, Intellectual Property Rights and confidentiality obligations, to ensure that such Sublicensee is subject to, and Suneva can comply with, all of Suneva’s covenants and obligations to Histogen under this
Agreement. Suneva’s rights to sublicense are limited as expressly set forth in this Section 2.2. Suneva shall (i) provide Histogen in writing a complete copy of each sublicense agreement entered by it under this
Agreement and (ii) name Histogen as a third party beneficiary in any such sublicense agreement; provided, however, that the requirements of the preceding clauses (i) and (ii) shall not apply with respect to sublicensing to contract sales
organizations, co-promotion partners, distributors and/or other service providers assisting Suneva or any Sublicensee in the commercialization of the Products ·(collectively, “Incidental
Sublicensees”). No such sublicense shall grant any right to grant further sublicenses without the prior, written consent of Histogen, such consent not to be unreasonably withheld. 

2.3 Right of First Negotiation for Rest of World 

During the period following the Effective Date through February 3, 2014 (“the Subject Period”), Histogen will not enter into a definitive
agreement to license, sell or otherwise grant rights to the Licensed Intellectual Property, in whole or in part, to a Third Party for use with a Product in the Field of Use outside the Territory except in accordance with the following procedure:

  

	 	(a)	 Within ten (10) business days of approval by Histogen’s Board of Directors of a detailed bona fide
term sheet to license or otherwise grant rights to the Licensed Intellectual Property for use with a Product in the Field of Use outside the Territory (“Bona Fide Term Sheet”) during the Subject Period, Histogen shall communicate to
Suneva all material terms of the Bona Fide Term Sheet (but not the identity of the proposed Third Party). 

  

	 	(b)	 Suneva shall have sixty (60) days, or such longer period as agreed to between Histogen and Suneva, to
enter into a definitive agreement with Histogen to acquire the Licensed Intellectual Property on substantially the same terms, which provide no lesser economic benefit to Histogen, as set forth in the Bona Fide Term Sheet. For the avoidance of
doubt, the parties shall negotiate in good faith with respect to the definitive agreement and neither Suneva nor Histogen shall have the right to negotiate a more favorable provision for itself than the provision as set forth in the Bona Fide Term
Sheet. If any usual or customary license provisions are not set forth in the Bona Fide Term Sheet, such provisions shall be negotiated in good faith. If any non-monetary provisions are set forth in the Bona
Fide Term Sheet that are unique to the proposed Third Party licensee, the parties will negotiate in good faith to adopt terms that are reasonably similar to such non-monetary provisions. 

  
 -9- 

 Confidential 

 

	 	(c)	 If the definitive agreement is not entered into by Suneva and Histogen within said (60) days, or such
longer period as agreed to between Histogen and Suneva, of Suneva’s receipt from Histogen of the Bona Fide Term Sheet, then Histogen may proceed with the transaction with any Third Party on terms no less favorable to Histogen than the terms set
forth in the Bona Fide Term Sheet. If a definitive agreement for such transaction with a Third Party is not entered into between Histogen and a Third Party within six (6) months after said sixty (60) days then before Histogen proceeds with
any Bona Fide Term Sheet, Histogen must re-offer the Bona Fide Term Sheet to Suneva pursuant to the procedures set forth in this Section 2.3(a) above. 

 

	 	(d)	 If Histogen proposes to enter into an agreement with a Third Party on terms less favorable to Histogen in their
entirety than were the terms set forth in the Bona Fide Term Sheet presented to Suneva pursuant to subpart (a) above, when all the terms are considered in their entirety as a package deal, then Histogen shall give written notice thereof to
Suneva, and Suneva shall have thirty (30) days after the receipt of said written notice to enter in to a definitive agreement on the same terms as specified in said written notice. 

2.4 Right of First Negotiation for Regulated Products 

Suneva shall have the right to negotiate and execute a partnership with Histogen for any products for which development begins after the Effective Date that
contain CCM or similar technology and which would require approval or clearance by Regulatory Authority prior to sale (“Regulated Products”). The financial terms of such a partnership will most likely be significantly different than
the terms of this Agreement. This right of first negotiation will lapse 60 days from the date that Histogen gives notice to Suneva of its intention to develop any Regulated Product (such notice must include a development plan containing the
therapeutic use of such Regulated Product along with Histogen’ s projected time lines and expenses associated with the development of the Regulated Product). The earliest date upon which Histogen may deliver such notice is the Effective Date.

 ARTICLE 3 

Regulatory Matters 
 3.1
Ownership and Maintenance of Regulatory Filings and Approvals 
 As between the parties, Suneva shall solely own any Regulatory Filings and Approvals
throughout the Territory that are either: (i) pending or in effect as of the Effective Date or (ii) made by or on behalf of it, or are obtained by or on behalf of it, following the Effective Date. Suneva, in its sole discretion, will be
responsible for the filing and maintenance of any Regulatory Filings and Approvals deemed necessary for the marketing of the Products. Histogen shall promptly notify Suneva in writing of any correspondence received from any Regulatory Authority
relating to any Product with respect to the manufacture of Product, Field of Use and the Territory, or Regulatory Filings and Approvals relating to any Product with respect to the Field of Use and the Territory, and shall provide Suneva with copies
of any such correspondence. Histogen will provide Suneva with reasonable assistance, at no charge to Suneva, with respect to Regulatory Filings and Approvals throughout the Territory that are either: (i) pending or in effect as of the Effective
Date or (ii) made by or on behalf of it, or are obtained by or on behalf of it, following the Effective Date. 

  
 -10- 

 Confidential 

 

 ARTICLE 4 

Delivery of Technical Information; Assistance; Development and Marketing; Non-Compete 

4.1 Delivery of Technical Information and CCM Technical Information 

Promptly after the Effective Date, and from time to time thereafter as may be reasonably requested by Suneva, Histogen shall deliver to Suneva, at no charge to
Suneva, copies of all Technical Information and CCM Technical Information reasonably in Histogen’s possession as of the Effective Date or, if applicable, at the time of any subsequent request. Histogen represents and warrants that Suneva has a
complete, current written description of the three liter CCM manufacturing process, i.e., all information necessary in order for a third party to produce CCM in a three liter reactor. Histogen will update this information to include any subsequent
improvements, adjustments or refinements of the CCM manufacturing process, including any changes related to any movement to a ten liter or larger scale. Notwithstanding the foregoing, Histogen covenants that as soon as available, but no later than
October 1, 2013, Histogen will deliver to Suneva, at no charge to Suneva, copies of all Technical Information and CCM Technical Information which will represent a complete written description of the ten liter CCM manufacturing process, i.e.,
all information necessary in order for a third party to produce CCM in a ten liter reactor. 
 4.2 Development and Commercialization

 4.2.1 Subject to Section 4.2.3 and Histogen’s performance of its obligations under the Supply
Agreement, and further subject to any required Regulatory Authority approvals, Suneva shall use commercially reasonable efforts, itself and/or through the activities of Sublicensees, to commercialize Products in the Territory. 

4.2.2 Subject to this Section 4.2, Suneva shall have sole discretion over all regulatory, marketing, pricing,
promotion, strategy, reimbursement, branding, distribution and sales issues relating to any Product in the Field of Use in the Territory. 

4.2.3 The parties acknowledge and agree that, notwithstanding anything to the contrary: (i) the obligations of Suneva with respect to the
Products under this Section 4.2 are expressly conditioned upon, among other things, the continuing absence of any material adverse condition or event beyond Suneva’s reasonable control relating to the safety, efficacy
or commercial viability of the Product, and the obligations of Suneva under this Section 4.2 shall be delayed or suspended so long as any such material adverse condition or event exists and (ii) in addition, Suneva
shall not be in breach of this Agreement for any failure to meet any of its obligations under this Section 4.2, to the extent such failure is attributable to any delay or other act or omission of Histogen or any Regulatory
Authority, or any other cause outside the reasonable control of Suneva. 
 4.3 Supply Agreement 

4.3.1 Manufacturer 
 The parties acknowledge that
pursuant to the Supply Agreement, Histogen has agreed to manufacture CCM for Suneva. The parties anticipate that Suneva initially will obtain a supply of CCM from Histogen pursuant to the Supply Agreement, and acknowledge that Suneva reserves the
right to transfer any or all of the services provided by Histogen under the Supply Agreement to a Third Party only under the circumstances set forth in and subject to the Supply Agreement. 

  
 -11- 

 Confidential 

 

 4.4 Non-Diversion: Histogen. 

During the Term, neither Histogen nor its Affiliates will, without the written consent of Suneva, directly or indirectly manufacture, sell, license,
distribute, supply, commercially exploit, make available, or otherwise directly or indirectly provide or divert any amounts of either CCM or any Product (or grant any rights in relation to any of the foregoing) for, or to any Person other than
Suneva or its Affiliates in the Territory within the Field of Use (a “Direct Diversion”). In addition, Histogen shall use commercially reasonable efforts to ensure that none of its distributors nor its licensees will engage in any
activities that if taken by Histogen would be a Direct Diversion (an “Indirect Diversion” and together with a Direct Diversion, a “Histogen Diversion”). Such commercially reasonable efforts shall include
(i) requiring all future licensees and distributors to agree to negative covenants concerning Indirect Diversions, and (ii) Histogen’ s reasonable enforcement of such covenants. 

In the event that Histogen becomes aware of a material Histogen Diversion, Histogen shall promptly provide Suneva with written notice of such Histogen
Diversion. Such notice shall describe the facts concerning such Histogen Diversion to the best of Histogen’s knowledge, and Histogen’s strategy to prevent the continuation of such Histogen Diversion. In the case of a material Direct
Diversion, Histogen shall take such actions as are necessary to cause the termination of such Direct Diversion. In the case of an Indirect Diversion, shall use commercially reasonable efforts to cause the termination of such Indirect Diversion. If,
(i) in the case of a Direct Diversion, Histogen shall fail to terminate such Direct Diversion or (ii) in the case of an Indirect Diversion, Histogen shall (a) fail to use commercially reasonable efforts to cause the termination of
such Indirect Diversion or (b) despite the use of commercially reasonable efforts such Indirect Diversion shall continue for a period of one hundred eighty (180) days thereafter, Histogen shall compensate Suneva for any losses incurred as
a result of such Histogen Diversion incurred on and after the date which is one hundred and eighty (180) days following Histogen obtaining actual knowledge of such Histogen Diversion. The parties hereto agree that a reasonable estimate of
Suneva’s losses under such a circumstance shall be two (2) times Suneva’s lost gross profit on the Product that is the subject of such Histogen Diversion. As such the parties hereto agree to such amount as liquidated damages, and not
as a penalty. For the avoidance of doubt, to the extent that there are multiple Histogen Diversions, each Histogen Diversion shall be treated as a separate and independent event hereunder. 

4.5 Non-Diversion: Suneva. 

During the Term, neither Suneva nor its Affiliates will, without the written consent of Histogen, directly or indirectly manufacture, sell, license,
distribute, supply, commercially exploit, make available, or otherwise directly or indirectly provide or divert any amounts of either CCM or any Product (or grant any rights in relation to any of the foregoing) for, or to any Person other than
Histogen or its Affiliates outside of the Territory and the Field of Use (a “Direct Diversion”). In addition, Suneva shall use commercially reasonable efforts to ensure that none of its distributors nor its licensees will engage in
any activities that if taken by Suneva would be a Direct Diversion (an “Indirect Diversion” and together with a Direct Diversion, a “Suneva Diversion”). Such commercially reasonable efforts shall include (i) requiring
all future licensees and distributors to agree to negative covenants concerning Indirect Diversions, and (ii) Suneva’s reasonable enforcement of such covenants. 

  
 -12- 

 Confidential 

 

 In the event that Suneva becomes aware of a material Suneva Diversion, Suneva shall promptly provide Histogen
with written notice of such Suneva Diversion. Such notice shall describe the facts concerning such Suneva Diversion to the best of Suneva’s knowledge, and Suneva’s strategy to prevent the continuation of such Suneva Diversion. In the case
of a material Direct Diversion, Suneva shall take such actions as are necessary to cause the te1mination of such Direct Diversion. In the case of an Indirect Diversion, shall use commercially reasonable efforts to cause the termination of such
Indirect Diversion. If, (i) in the case of a Direct Diversion, Suneva shall fail to terminate such Direct Diversion or (ii) in the case of an Indirect Diversion, Suneva shall (a) fail to use commercially reasonable efforts to cause
the termination of such Indirect Diversion or (b) despite the use of commercially reasonable efforts such Indirect Diversion shall continue for a period of one hundred eighty (180) days thereafter, Suneva shall compensate Histogen for any
losses incurred as a result of such Suneva Diversion incurred on and after the date which is one hundred and eighty (180) days following Suneva obtaining actual knowledge of such Suneva Diversion. The parties hereto agree that a reasonable
estimate of Histogen’s losses under such a circumstance shall be two (2) times Histogen’s lost gross profit on the Product that is the subject of such Suneva Diversion. As such the parties hereto agree to such amount as liquidated
damages, and not as a penalty. For the avoidance of doubt, to the extent that there are multiple Suneva Diversions, each Suneva Diversion shall be treated as a separate and independent event hereunder. 

4.6 Non-Compete 

For so long as Suneva, its Affiliates or any Sublicensee has rights to the Licensed Intellectual Property, neither Histogen nor any of its Affiliates shall
develop, manufacture, market or sell ( or license or assist any Third Party to develop, manufacture, market or sell) in the Field of Use in the Territory any (i) topical product containing CCM as an ingredient (whether alone or in combination
with any other ingredient) and/or (ii) Similar Product. It is expressly understood, however, that Histogen may develop Regulated Products, subject to Suneva’s Right of First Negotiation under Section 2.4. 

ARTICLE 5 
 Ownership of
Intellectual Property 
 5.1 Ownership of Intellectual Property 

As between the parties all right, title and interest (including, without limitation, any patent rights, copyrights, trade secrets and other Intellectual
Property Rights) in and to the Patent Rights, Technical Information and Histogen Improvements shall remain the sole and exclusive property of Histogen. As between the parties all right, title and interest (including, without limitation, any patent
rights, copyrights, trade secrets and other Intellectual Property Rights) in and to the Suneva Improvements (including, but not limited to, all data generated by or on behalf of Suneva in connection with the development or marketing of any Product,
but excluding any Licensed Intellectual Property that may be used in connection with or incorporated into any Product) and 

  
 -13- 

 Confidential 

 

 
the Trademark shall vest solely in Suneva. Neither party will through this Agreement, whether by implication, estoppels or otherwise, obtain any rights to the other party’s proprietary
technology or Intellectual Property Rights except for such licenses and other rights as are expressly provided for in this Agreement. All rights not expressly granted by a party under this Agreement are reserved to such party. 

5.2 Joint Intellectual Property 
 Histogen
and Suneva shall jointly and undividedly own all right, title and interest in any Joint Improvements and any Joint Patents, provided that Histogen’s rights in such Joint Improvements and Joint Inventions shall remain subject to the restrictions
and obligations herein with respect to Licensed Intellectual Property. Excepting only as set forth in this Agreement, each joint owner shall be entitled to use, transfer and exploit its rights in the Joint Improvements and Joint Patents without any
consent from the other joint owner, and without any accounting to the other joint owner. 
 5.3 License Grant by Suneva 

5.3.1 Manufacturer 
 Subject to the terms and
conditions of this Agreement, Suneva hereby grants to Histogen, and Histogen accepts a non-exclusive, royalty-free, worldwide, transferable (to the extent permitted under Section 15.2
below) license, under the Suneva Improvements, and Suneva’s interest in any Joint Improvements and the Joint Patents, solely to manufacture CCM for Suneva pursuant to the Supply Agreement. 

5.3.2 Histogen’s Business 
 Suneva hereby
grants to Histogen the right to acquire a license to use and practice the Suneva Improvements for Histogen’s own business purposes, subject to Histogen’s paying a commercially reasonable earned royalty in an amount to be mutually approved
by the parties, as determined by a mutually-approved licensing valuation expert. 
 ARTICLE 6 

Financial Terms 
 6.1
Reserved 
 6.2 Royalties 

6.2.1 
  

	 	(a)	 During the Royalty Term, subject to Section 6.3, and
Section 6.2.l(b) and (c), Suneva shall pay to Histogen royalties based on Net Sales of Products (the “Royalties”) equal to * percent (*%). 

  
 -14- 

 Confidential 

 

	 	(b)	 In the event Net Sales of Products outside of USA exceed $50 million in any calendar year, the royalty
rate on all such excess Net Sales shall be increased by * percent, to *%. 

  

	 	(c)	 In the event Net Sales of Products outside of USA exceed $100 million in any calendar year, the royalty
rate on all such excess Net Sales shall be increased by an additional * percent, to *%. 

 6.2.2 At any time during the
Royalty Term, if there is Competition in the Territory, then, on a Product-by-Product basis, the applicable royalty rate set forth in
Section 6.2.1 will be reduced to * percent (*%). In the event of a dispute as to whether a product is a “Similar Product” for purposes of determining whether Competition exists, the Parties agree to submit that
issue (and only that issue) to binding arbitration before a single arbitrator in accordance with the rules of the American Arbitration Association, but without the right of either party to take discovery of the other and with both parties sharing
equally the administrative and arbitrator’s fees and bearing all of their own legal fees. It is understood that no reduction in royalty under this clause will be effective until the dispute is resolved either informally or by the arbitrator and
that in the event the existence of a “Similar Product” is determined, a refund of the royalty differential will be made by Histogen to Suneva as of the date Suneva first notified (pursuant to Section 15.8)
Histogen of Competition. 
 6.2.3 At any time during the Royalty Term, if any Product is no longer Covered by Valid Claim, then the
applicable royalty rate set for such Product forth in Section 6.2.1 will be reduced to * half percent (*%). 

6.2.4 Suneva shall pay the Royalties on a quarterly basis within forty-five ( 45) days after the end of each calendar qua1ier. 

6.2.5 As a result of the good-faith negotiations conducted by the Parties pursuant to the former Section 6.2.5 of the Original Agreement,
the Parties have agreed to a $* minimum annual royalty, to be paid $* each quarter by the first day of each calendar quarter. The Parties agree to re-visit the minimum annual royalties no later than
June 1, 2014 and June 1 of each subsequent year. It is further understood that in any year in which Suneva should fail to achieve the requisite sales at the applicable royalty rate to fund the agreed-upon minimum annual royalties, then at
Suneva’s option this Agreement will either revert to a non-exclusive license without any minimum annual royalties or Suneva will make the minimum royalty payment and preserve this Agreement’s
exclusivity and any existing minimum royalty obligations. In the event of a breach of this Agreement or the Supply Agreement by Histogen, with any such breach that is subject to cure remaining uncured thirty (30) days following Suneva’s
notice of breach to Histogen, including but not limited to a failure to supply CCM in response to a Purchase Order issued pursuant to Section 3.1 of the Supply Agreement, Suneva shall be relieved of any minimum royalty obligation. 

6.3 Royalty Adjustments 
 If it is legally
necessary for Suneva to obtain a license under any Third Party’s Patent rights in order to manufacture, use or sell the Product as developed by Histogen in the Territory for the Field of Use, then Histogen shall have the first right to obtain
such license for the Territory from 

  
 -15- 

 Confidential 

 

 
such Third Party and include such rights under the Licensed Intellectual Property licensed to Suneva under this Agreement. If Histogen does not wish to obtain such license, then it will so notify
Suneva and Suneva may obtain a license to such Third Party Patent rights, as applicable, for the Field of Use in the Territory. In either case, during the Term of this Agreement for so long as Suneva is obligated to pay royalties hereunder, any
royalties owed by Suneva to a Third Party under the license agreement with such Third Party solely with respect to the license of the right to practice such Third Party Patent right with respect to the Product for the Territory shall be deducted
from the royalty payments due to Histogen from Suneva. If Histogen is the party that obtains such license, then Histogen shall solely bear the cost of any amounts paid to the applicable Third Party licensor. If Suneva is the party that obtains such
license, then Suneva may offset the amounts paid to the applicable Third Party licensor against Royalties owed Histogen under this Agreement For avoidance of doubt, this section is not applicable to any Third Party Patent Rights that may be
infringed by an Improvement or some enhancement or addition to a Product that is created or developed by Suneva. 
 6.4 Form of Payment;
Late Payments; Disputed Payments 
 Unless otherwise agreed to by the parties, all payments under this Agreement shall be paid in United States Dollars.
If Suneva fails to pay any amount due under this Agreement by the applicable due date, without limiting any other remedies that may then be available to Histogen (including, without limitation, termination for material breach pursuant to
Section 10.2), Histogen will have the right to assess late charges in an amount equal to the lesser of one-percent (1.0%) per month or the maximum amount allowed under Applicable Law, whichever is lower.
Notwithstanding the foregoing, late charges shall not apply in respect of amounts that Suneva disputes in good faith. 
 ARTICLE 7

 Reports and Records 

7.1 Records and Audits 
 Suneva shall keep
such books of account containing complete and accurate particulars as may be reasonably necessary for the purpose of showing the amounts payable to Histogen under this Agreement during the most recent three (3) year period. During the Term and
for three (3) years thereafter, Suneva shall make such books of account available (no more than once per year upon reasonable prior written notice to Suneva) for inspection by Histogen’s designated accounting firm reasonably acceptable to
Suneva, for the purpose of verifying Suneva’s Royalty Statements (as defined below). Histogen shall be responsible for the cost of any such inspection; provided, however, that if an inspection shows for any audited period an underpayment in
excess of five percent (5%) of Royalties payable hereunder for such period, then Suneva shall reimburse Histogen for the reasonable, documented cost of the inspection at the time Suneva pays the Royalties that are past due. In the event that any
such inspection reveals an underpayment or an overpayment in the amount of Royalties or other payments that should have been paid by Suneva to Histogen, then the underpayment amount shall be paid, or the overpayment amount shall be returned (as
applicable), within thirty (30) days after the party to receive such payment makes a demand therefor. Histogen shall cause its accounting firm to retain all information subject to review under this Section 7.1 in confidence. In addition,
Suneva shall have the right to require 

  
 -16- 

 Confidential 

 

 
that such accounting firm, prior to conducting such inspection, enter into a reasonable nondisclosure agreement with Suneva regarding such information. Histogen will cause its accounting firm to
make all results of any such inspection available to Suneva. The accounting firm shall disclose to Histogen only whether Suneva’s Royalty Statement(s) and/or other payments made under this Agreement are correct or not and the amount of any
discrepancy. No other information shall be shared with Histogen. Histogen shall treat all such information as Suneva’s Confidential Information (as defined in Section 14.2). 

7.2 Royalty Statements 
 Within forty-five
(45) days after the end of each calendar quarter during which any Net Sales occur, Suneva shall deliver to Histogen a complete and accurate report, giving such particulars of the business conducted by Suneva during the preceding quarter under
this Agreement as are pertinent to an accounting of Royalties that may be due to Histogen under this Agreement (the “Royalty Statement”). The Royalty Statement shall include the following: 

 

	 	(a)	 gross amounts invoiced for each Product by Suneva and its Affiliates and any Sublicensees for such calendar
quarter; 

  

	 	(b)	 the calculation of Net Sales for such calendar quarter; 

 

	 	(c)	 a breakdown of Royalties due based on such Net Sales (less any minimum royalties paid); 

 

	 	(d)	 a copy of each report from each Sublicensee as may be pe1iinent to an accounting of Royalties and other
payments that may be due to Histogen. 

 Each Royalty Statement shall clearly delineate USA sales and
non-USA sales. 
 ARTICLE 8 

Prosecution and Maintenance of Patent Rights 

8.1 Prosecution and Maintenance 

8.1.1 By Histogen 
 Histogen shall have the
exclusive right (but not the obligation) to prepare, file and prosecute all patent applications included in the Patent Rights (including, without limitation, any Patents Covering Histogen Improvements) and maintain in force any issued patents
included in the Patent Rights in the Territory. Histogen shall bear all attorney’s fees, filing and maintenance fees and other costs and expenses incurred in connection with the foregoing activities. Histogen shall control such preparation,
filing, prosecution and maintenance activities, using counsel reasonably acceptable to Suneva; provided, however, that (i) Histogen shall keep Suneva reasonably informed with respect to the status and progress of any such application filings
and prosecution and maintenance activities, and (ii) Histogen shall promptly provide Suneva with copies of all filed applications, office actions received by Histogen, office action responses filed by Histogen and other material correspondence
received or submitted by Histogen relating thereto. 

  
 -17- 

 Confidential 

 

 8.1.2 By Suneva 

Should Histogen decide that it is no longer interested in filing, maintaining or prosecuting a particular Patent Right in the Territory, it shall promptly
advise Suneva of this decision, sufficiently in advance to permit Suneva to undertake such filing, maintenance and prosecution without a loss of rights. Thereafter, Suneva may assume such filing, prosecution and maintenance at its sole expense by
written notice to Histogen, in which event such Patent Right shall, at Suneva’s option, be assigned to Suneva at no charge and Suneva shall have no further obligation to pay royalties on Products Covered by such Patent Right. 

ARTICLE 9 
 Enforcement
of and Challenges to Licensed Intellectual Property 
 9.1 Infringements 

9.1.1 Notice of Potential Infringement. 
 During
the Term, if either party learns of any potential infringement, unauthorized use or misappropriation, or claim of ownership by a Third Party with respect to the Licensed Intellectual Property in connection with any Product in the Territory for the
Field of Use (each, a “Potential Infringement”), such party shall promptly notify the other party in writing, and shall promptly provide such other party with available evidence, of such Potential Infringement. 

9.1.2 Prosecution of Potential Infringements. 

Histogen shall have the exclusive right, but not the obligation, to attempt to resolve such alleged Potential Infringement (excluding any Potential
Infringement relating to any Joint Patent or Joint Improvement) at its own expense, including without limitation the filing of an infringement suit using counsel of its own choice. If Histogen does not secure cessation of such Potential Infringement
or institute an infringement proceeding against an offending Third Party within ninety (90) days after learning of such Potential Infringement (or if Histogen earlier determines that it does not wish to take action with respect to such
Potential Infringement), then Suneva shall have the right to commence an infringement proceeding at its own expense on behalf of Histogen (if necessary with Histogen as a named co-party) or otherwise resolve
such Potential Infringement. 
 9.1.3 Cooperation; Awards. 

Each party shall execute all necessary and proper documents, take such actions as shall be appropriate to allow the other party to institute and prosecute such
Potential Infringement actions and shall otherwise cooperate in the institution and prosecution of such actions (including, without limitation, consenting to being named as a party thereto). Any award paid by Third Parties as a result of an action
undertaken pursuant to this Section 9.1 (whether by way of settlement or otherwise) shall be allocated as follows: 

  
 -18- 

 Confidential 

 

	 	(i)	 if Histogen has instituted and maintained such action, Histogen shall be entitled first to deduct all costs and
expenses incurred by Histogen with respect to such action and from any remainder shall reimburse Suneva for any costs and expenses incurred by Suneva with respect to such action and, if after such deduction and reimbursement any funds remain,
Histogen shall pay Suneva (a) as to ordinary damages collected, an amount equal to 60% of such remaining damages and (b) as to special, treble or punitive damages collected, the parties shall share equally in such award; and

  

	 	(ii)	 if Suneva has instituted and maintained such action, Suneva shall be entitled first to deduct all costs and
expenses incurred by Suneva with respect to such action and from any remainder shall reimburse Histogen for any costs and expenses incurred by Histogen with respect to such action and, if after such deduction and reimbursement any funds remain, then
(a) as to ordinary damages collected, Suneva shall pay Histogen 20% of such remaining damages and (b) as to special, treble or punitive damages collected, the parties shall share equally in any award. 

9.1.4 Neither party is obligated to incur any costs for policing any Joint Patent or for enforcing or defending any Joint Patent against any
Third Party. Notwithstanding the foregoing, a party will notify the other party in writing prior to commencing any enforcement actions of Joint Patents against any Third Party. Any enforcement or defense of any Joint Patent that is mutually
undertaken by both parties requires separate agreement between the parties. If one of the parties provides the other party written notice of its decision not to participate in an enforcement action of any Joint Patents and the other proceeds, the
proceeding party has no obligation to account to the non-participating party for any amounts collected. 

9.2 Invalidity Claims 
 If a Third Party at
any time asserts a claim that any of the Patent Rights in relation to a Product in the Territory for the Field of Use is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement action
brought by either party pursuant to Section 9.1 or otherwise, Histogen shall have the exclusive right (but not the obligation) to contest or defend against such Invalidity Claim (including the right to take over the sole
defense of the Invalidity Claim if the infringement action was initially brought by Suneva), at its own expense using its own counsel reasonably acceptable to Suneva. Histogen shall not, without Suneva’s prior, written approval, settle such
Invalidity Claim in a manner that would reasonably be expected to have an adverse impact on Suneva’s rights hereunder. 
 ARTICLE 10

 Term and Termination 

10.1 Term 
 This Agreement shall become
effective on the Effective Date and, unless and until terminated pursuant to Section 10.2, Section 10.3, Section 10.4 or Section 10.5, shall
continue in effect until the later of (i) the expiration of the last-to-expire of the Patent Rights which has at least one Valid Claim Covering such Product in the
Territory or (ii) fifteen (15) years from the Effective Date (the “Initial Term”). Thereafter, this Agreement will automatically renew, unless and until terminated pursuant to Section 10.2,
Section 10.3, Section 10.4 or Section 10.5, for successive 5-year periods each of which shall be known as a “Renewal
Term” (the Initial Term and all subsequent Renewal Terms shall be known as the “Term”). 

  
 -19- 

 Confidential 

 

 10.2 Termination for Material Breach 

Upon any material breach of this Agreement by a party, including, without limitation, failure of a party to pay any amounts due to the other party or to supply
CCM in accordance with the terms of the License or Supply Agreement, the other party shall have the right to terminate this Agreement by giving sixty (60) days prior, written notice to the breaching party; provided, however, that this Agreement
shall not terminate if the breaching party has cured such breach by the end of such sixty (60) day period. Notwithstanding anything herein to the contrary, if the nature of the breach is such that additional time is reasonably needed for the
breaching party to cure such breach, and the breaching party has during such sixty (60) day period commenced good faith and diligent efforts to cure such breach, then the other party shall provide the breaching party with additional time beyond
such sixty (60) day period as reasonably necessary for the breaching party to cure such breach (but in any event, not more than four ( 4) months after the date of the breach notice), provided that the breaching party continues to act in good
faith and diligently to cure such breach during any such extension period. 
 10.3 Termination for Challenges to Patent Rights 

Histogen shall have the right to terminate this Agreement in its entirety, immediately upon the issuance of written notice to Suneva, if at any time Suneva or
any of its Affiliates or Sub licensees challenges the validity, enforceability or scope of any of the Patent Rights in any court or before any governmental authority with authority to determine the validity, enforceability or scope of such Patent
Rights, or cause or request, without the prior written approval of Histogen, a review by any such court or governmental authority of the same. 

10.4 Termination for Bankruptcy or Insolvency 

Either party hereto shall have the right to terminate this Agreement immediately by written notice to the other party (i) if the other party is declared
insolvent or bankrupt by a court of competent jurisdiction, (ii) if a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against the other party and such petition is not dismissed within ninety
(90) days after filing or (iii) if the other party shall make or execute an assignment of substantially all of its assets for the benefit of creditors. Each of the events described in this Section 10.4 shall be
known as an “Insolvency Event.” 
 10.5 Termination for Convenience by Suneva 

Suneva shall have the right at any time to terminate this Agreement m its entirety, for convenience, by giving one ( 1) year’s notice thereof in writing
to Histogen. 

  
 -20- 

 Confidential 

 

 10.6 Consequences of Termination 

10.6.1 License 
 Upon any termination of this
Agreement by either party, the license granted to Suneva under Section 2.1 shall terminate, subject to Section 10.6.2 below, and all other rights and licenses granted to Suneva herein shall
terminate and revert to Histogen on termination. 
 10.6.2 Sublicenses 

Notwithstanding anything to the contrary, upon any termination of this Agreement by either party, any sublicenses of the Licensed Intellectual Prope1iy under
each agreement pursuant to which such a sublicense was granted under this Agreement to a Sublicensee shall, to the extent not imposing obligations on Histogen in excess of or materially different from those contained herein and to the extent
benefitting and protecting Histogen in substantially and materially the same manner contained herein, at the election of Histogen, either: (i) be terminated automatically once Suneva notifies the applicable Sublicensee that it is exercising any
termination right provided for in the applicable sublicense agreement; or (ii) survive such termination and be automatically assigned to Histogen in order to provide for the applicable Sublicensee’s continued enjoyment of their rights
under such sublicense agreement; provided that the applicable Sublicensee is not in breach or default of any terms of their sublicense agreement or of this Agreement as of the date Histogen’s notice of election is received by Suneva.. Histogen
shall notify Suneva of its election within ten (10) business days following the effective date of termination of this Agreement. Failure to provide such notice to Suneva by 5:00 p.m. EST on the last day of the ten (10) business day period
will result in the automatic termination of all of Suneva’s sublicenses granted hereunder at such time. 
 10.6.3 Inventory 

Notwithstanding anything to the contrary, for one hundred eighty (180) days following the effective date of any termination of this Agreement (the
“Sell-Off Period”), Suneva shall have the right, but not the obligation, to sell-off any excess Product that was manufactured and packaged or on order
prior to the effective date of termination, subject to its compliance with the terms of this Agreement applicable to any such sales made during that period. Any amounts generated during the Sell-Off Period in
connection with the sale of Products shall be subject to the payment of Royalties and the other payment provisions set forth herein. 

10.6.4 Confidential Information 
 Except as
otherwise provided herein, upon termination of this Agreement, all remaining records and materials in a party’s possession or control containing the other party’s Confidential Information and to which the former party does not retain
rights hereunder, shall promptly be returned or destroyed at the request of the disclosing party. Notwithstanding the foregoing, one copy of such records may be retained by legal counsel for the former party solely for archival purposes. 

  
 -21- 

 Confidential 

 

 10.7 Survival 

The following provisions shall survive any termination or expiration of this Agreement: Article 1 (“Definitions”), Article 5
(“Ownership of Intellectual Property”), Article 7 (“Reports and Records”), Section 10.6 (“Consequences of Termination”), this Section 10.7
(“Survival”), Article 11 (“Representations and Warranties”), Article 12 (“Limitation of Liability”), Article 13
(“Indemnification”), Article 14 (“Confidentiality”) and Article 15 (“General Provisions”). 

10.8 Remedies 
 Neither party shall incur
any liability whatsoever for any damage, loss or expense of any kind suffered or incurred by the other (or for any compensation to the other) arising from or incident to any termination of this Agreement which complies with the terms of this
Agreement whether or not such party is aware of any such damage, loss or expense. Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain available except as expressly
agreed to otherwise herein. 
 ARTICLE 11 

Representations and Warranties 

11.1 Mutual Representations and Warranties 

Each party hereby represents, warrants and covenants as of the Effective Date and at all times during the Term thereafter as follows: 

11.1.1 Organization. 
 Such party (i) is a
company duly organized, validly existing and in good standing under the laws of the jurisdiction where such company was formed or incorporated, and (ii) has all necessary company power and authority to own its properties and to conduct its
business, as currently conducted. 
 11.1.2 Authorization. 

The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby are within the company power of such party, have been
duly authorized by all necessary company proceedings of such party, and this Agreement has been duly executed and delivered by such party. 

11.1.3 No Conflict. 
 The execution and delivery
of this Agreement and the consummation of the transactions contemplated herein as of the Effective Date do not, and after the Effective Date will not: (i) conflict with or result in a breach of any provision of such party’s organizational
documents; (ii) result in a material breach of any material agreement to which such party is bound; (iii) result in a violation of any judicial order to which such party is subject; (iv) require such party to obtain any material
approval or consent from any governmental authority or other Third Party other than those consents and approvals which have been obtained prior to the date hereof or are expressly contemplated herein; or (v) to the knowledge of such party,
violate any Applicable Law applicable to such party in any material respect. 

  
 -22- 

 Confidential 

 

 11.1.4 Enforceability. 

This Agreement constitutes the valid and binding obligation of such party, enforceable against such party in accordance with its terms, subject to bankruptcy,
reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an action at law). 

11.2 Representations and Warranties of Histogen. 

In addition, Histogen hereby represents, warrants and covenants as of the Effective Date, and at all times during the Term thereafter, as follows: 

11.2.1 Title to Licensed Intellectual Property. 

Histogen solely owns, and at all times shall maintain sole ownership of, all right, title, and interest in and to the Licensed Intellectual Property, including
the exclusive, absolute, irrevocable right, title and interest thereto, free and clear of any encumbrances except as disclosed on Schedule A. There are no inventors of Patent Rights other than those listed as inventors on patent applications filed
for such Patent Rights. 
 11.2.2 No Other Assets. 

Other than the Licensed Intellectual Property, neither Histogen nor any of its Affiliates (collectively, the “Histogen Parties”), holds any
ownership, license or other right in or to any Intellectual Property Rights necessary for the development manufacture, use, sale or commercialization of any Product in the Field of Use in the Territory. 

11.2.3 No Infringement. 
 To the knowledge of the
Histogen Parties, neither the Licensed Intellectual Property, nor the development, use, manufacture, sale, offer for sale or import of any Product in the Field of Use in the Territory, does or will infringe, or misappropriate any Patent, copyright,
trademark, service mark, trade secret or other Intellectual Property Right of any Third Party. Other than as specifically disclosed in a writing addressed to Suneva’s General Counsel that references this
Section 11.2.3, none of the Histogen Parties have received any written notice from any Third Party asserting any of the foregoing. 

11.2.4 No Challenges to Validity or Enforceability. 

To the knowledge of the Histogen Parties, the Licensed Intellectual Property is and shall be valid and enforceable. Other than as specifically disclosed in a
writing addressed to Suneva’s General Counsel that references this Section 11.2.4, the validity or enforceability of the Licensed Intellectual Property and the title of Histogen or any other Histogen Party thereto has
not been questioned in any litigation, governmental inquiry or proceeding to which any Histogen Party is or was a party and, to the knowledge of the Histogen Parties, no such litigation, governmental inquiry or proceeding is threatened. 

  
 -23- 

 Confidential 

 

 11.2.5 No Known Infringements by Third Parties. 

To the knowledge of the Histogen Parties, there has not been and is not currently any infringement, misappropriation or unauthorized use by any Third Party of
any of the Licensed Intellectual Property. 
 11.2.6 Preservation of Trade Secrets. 

The Histogen Parties have taken commercially reasonable actions necessary or appropriate to preserve the confidentiality of all trade secrets, proprietary data
and other confidential information included in the Technical Information. 
 11.2.7 Absence of Claims. 

Other than as specifically disclosed in a writing addressed to Suneva’s General Counsel that references this Section 11.2.7: (i)
there are no suits or actions, administrative, arbitration or other proceedings, to the knowledge of the Histogen Parties, or, governmental investigations, pending or threatened against any of the Histogen Parties with respect to CCM, the ReGenica
Products or any of the Licensed Intellectual Property, (ii) no Person has notified any of the Histogen Parties in writing of any threatened claim with respect to any of the foregoing and (iii) there is no judgment, order, injunction,
decree, writ or award against any of the Histogen Parties that is not satisfied and remains outstanding with respect to any of the foregoing. 

11.2.8 Compliance With Law; Regulatory Matters. 

No written communication has been received by any of the Histogen Parties, and to the knowledge of the Histogen Parties no regulatory enforcement action or any
related review or investigation by any Regulatory Authority or other governmental authority is pending or threatened with respect to any alleged or actual violation by any of the Histogen Parties of any Applicable Law or other requirement of any
Regulatory Authority or other governmental authority relating to the development, clinical trials or other operations conducted by any of the Histogen Parties with respect to any of the Licensed Intellectual Property for any Product. All Technical
Information has been developed by the Histogen Parties in accordance with Applicable Law. 
 11.2.9 Past Product Activities. 

All past activities by Histogen relating to the development, sales, marketing and commercialization of the Products have been conducted in accordance with
Applicable Law. Histogen is not aware of any safety issues or concerns regarding the Products and all historical adverse events relating to the Products have been disclosed to Suneva’s General Counsel in a writing that references this
Section 11.2.9. There have been no serious adverse events related to any of the Products. 

  
 -24- 

 Confidential 

 

 11.3 Representations and Warranties of Suneva. 

In addition, Suneva hereby represents, warrants and covenants as of the Effective Date as follows: 

11.3.1 Compliance With Law; Regulatory Matters. 

Suneva will act in accordance with Applicable Law with respect to the sales and marketing of any Products. No written communication has been received by
Suneva, and no regulatory enforcement action or any related review, or to the knowledge of Suneva, investigation, by any Regulatory Authority or other governmental authority is or at any time prior to the Effective Date, has been, pending ( or, to
the knowledge of Suneva, is or at any time prior to the Effective Date, has been, threatened by any Regulatory Authority or other governmental authority) with respect to any alleged or actual violation by Suneva of any Applicable Law or other
requirement of any Regulatory Authority or other governmental authority relating to the development, clinical trials and other operations conducted by Suneva. 

11.3.2 No Inconsistency. 
 Suneva is not currently
a party to, and during the Term of this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under this Agreement. 

11.4 DISCLAIMER 
 EXCEPT AS EXPRESSLY SET
FORTH IN THIS ARTICLE 11, NEITHER PARTY MAKES, AND EACH HEREBY EXPRESSLY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND IN CONNECTION WITH THIS AGREEMENT, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR ANY WARRANTIES ARISING FROM A COURSE OF DEALING, COURSE OF PERFORMANCE OR USAGE OF TRADE. WITHOUT LIMITING THE GENERALITY OF
THE FOREGOING, NEITHER PARTY MAKES, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS, ANY REPRESENTATION OR WARRANTY IN CONNECTION WITH THIS AGREEMENT (I) THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF THE PRODUCTS PURSUANT TO THIS
AGREEMENT WILL BE SUCCESSFUL, THAT ANY PRODUCT WILL OBTAIN MARKETING AUTHORIZATION APPROVAL IN THE TERRITORY OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO THE PRODUCTS WILL BE ACHIEVED OR (II) REGARDING THE EFFECTIVENESS, VALUE, SAFETY,
NON-TOXICITY OR PATENTABILITY OF ANY LICENSED INTELLECTUAL PROPERTY, PRODUCTS OR ANY RESULTS PROVIDED BY EITHER PARTY PURSUANT TO THIS AGREEMENT. NOTHING IN THIS SECTION 11.4 SHALL BE CONSTRUED TO LIMIT OR EXCLUDE ANY REPRESENTATION OR
WARRANTY EXPRESSLY MADE IN THE SUPPLY AGREEMENT. 

  
 -25- 

 Confidential 

 

 ARTICLE 12 

Limitation of Liability 

12.1 LIMITATION OF LIABILITY 
 EXCEPT WITH
REGARD TO (I) DAMAGES ARISING FROM THE GROSS NEGLIGENCE, WILLFUL BREACH OR WILLFUL MISCONDUCT OF A PARTY, (II) ANY DUTY TO INDEMNIFY FOR DAMAGES PURSUANT TO A THIRD PARTY CLAIM UNDER ARTICLE 13
(“INDEMNIFICATION”) AND (III) DAMAGES FOR ANY PARTY’S INFRINGEMENT OR MISAPPROPRIATION OF A THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS OR FOR ANY PARTY’S BREACH OF THEIR CONFIDENTIALITY OBLIGATIONS HEREUNDER, TO THE
MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EITHER PARTY OR ANY OF THEIR RESPECTIVE AFFILIATES BE LIABLE FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR FOR ANY LOSS OF PROFITS, REVENUE OR INTEREST,
ARISING FROM OR IN CONNECTION WITH THIS AGREEMENT, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY AND IRRESPECTIVE OF WHETHER SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH LOSS OR DAMAGE. 

ARTICLE 13 

Indemnification; Insurance 

13.1 Mutual Indemnities; Indemnity Procedures 

13.1.1 Indemnity by Suneva. 
 Suneva shall defend,
indemnify and hold harmless Histogen and its Affiliates, and their respective members, managers, directors, employees, officers and agents (collectively, the “Histogen Indemnitees”) from and against any and all liability, demands,
damages, fines, costs and expenses (including, without limitation, reasonable legal fees and expenses) and losses (including, without limitation, with respect to death, personal injury, illness or property damage) incurred by or awarded to Third
Parties (collectively, “Losses”) which are required to be paid by any Histogen Indemnitee in connection with any Third Party claim, complaint, demand, suit, action, investigation or proceeding (collectively, “Third Party
Claims”) to the extent arising from any allegations: (i) which if true would constitute a breach by Suneva of any representation, warranty, covenant or other provision set forth in this Agreement, (ii) which if true would
constitute negligence or willful misconduct of any of the Suneva Indemnitees (as defined below) or Suneva’s Sublicensees. or (iii) that arise or result from the development, commercialization, manufacture, use, marketing, offer for sale,
sale, import, handling, storage, distribution or other disposition of Products by Suneva or its Sub licensees. The foregoing indemnity obligation shall not apply to the extent that such Losses result from or relate to either (A) negligence or
willful misconduct of a Histogen Indemnitee (B) the breach of this Agreement by a Histogen Indemnitee or (C) any dispute or conflict between a Histogen Indemnitee and a Third Party in existence prior to the Effective Date. 

  
 -26- 

 Confidential 

 

 13.1.2 Indemnity by Histogen. 

Histogen shall defend, indemnify and hold harmless Suneva and its Affiliates, and their respective members, managers, directors, employees, officers and agents
(collectively, the “Suneva Indemnitees”) from and against any and all Losses which are required to be paid by any Suneva Indemnitee in connection with any Third Party Claim against a Suneva Indemnitee to the extent arising from any
allegations: (i) which if true would constitute a breach by Histogen of any representation, warranty, covenant or other provision set forth in this Agreement, (ii) which if true would constitute negligence or willful misconduct of any of
the Histogen Indemnitees or (iii) that arise or result from the development, commercialization, manufacture, use, marketing, offer for sale, sale, import, handling, storage, distribution or other disposition of Products by a Histogen Indemnitee
prior to the Effective Date. The foregoing indemnity obligation shall not apply to the extent that such Losses result from or relate to either (A) negligence or willful misconduct of a Suneva Indemnitee or (B) the breach of this Agreement
by a Suneva Indemnitee or (C) any dispute between a Suneva Indemnitee and a Third Party in existence prior to the Effective Date. 

13.1.3 Indemnity Procedures. 
 In the event that
either party intends to seek indemnification for any Third Party Claim under Section 13.1.1, such party (the “Indemnified Party”) shall inform the other party (the “Indemnifying Party”) of
the Third Party Claim promptly after receiving notice of the Third Party Claim; provided, however, that any failure to provide such notice shall not relieve the Indemnifying Party of its obligations under this Article 13 except to the extent
the Indemnifying Party is materially prejudiced by such failure. The Indemnified Party shall permit the Indemnifying Party to direct and control the defense of such Third Party Claim and shall provide such reasonable assistance as is reasonably
requested by the Indemnifying Party (at the Indemnifying Party’s cost) in the defense of the Third Party Claim. In any such proceeding, the Indemnified Party, at its sole expense, shall have the right to retain its own counsel. Nothing in this
Article 13 or in Article 9 shall permit a party to make any admission on behalf of the other party, or to settle or dispose of any claim or litigation which would impose any financial obligations on the other party, or subject the
other party to an injunction or equitable relief, without the prior written consent of the other party, such consent not to be unreasonably withheld or delayed. 

13.2 Insurance 
 During the Term of this
Agreement and for five (5) years thereafter, each party shall maintain insurance with respect to its activities under this Agreement as is normal and customary in the industry generally for parties similarly situated. Each party shall, upon
request of the other party, provide the requesting party with a copy of the foregoing policies of insurance, along with any amendments and revisions thereto. 

  
 -27- 

 Confidential 

 

 ARTICLE 14 

Confidentiality 
 14.1
Confidentiality and Non-Use 
 14.1.1 Obligations 

Any information relating to a party’s business, technologies or finances, Intellectual Property Rights (including, but not limited to, in the case of
Suneva any reports and records provided under Article 7 and, in the case of Histogen, any Technical Information) disclosed to the other party under this Agreement that is marked or otherwise identified as proprietary or confidential at the
time of disclosure or that is of such a nature that a reasonable person would understand such information to be proprietary or confidential collectively constitutes that party’s “Confidential Information.” Neither party will use the
Confidential Information of the other party for any purpose unrelated to the exercise of its rights or fulfillment of its obligations under this Agreement, and each party will hold such Confidential Information in confidence during the Term and for
a period of ten (10) years after the termination or expiration date of this Agreement (except that Confidential Information identified by a party as a trade secret shall be held in confidence for as long as such information remains a trade
secret). Each party shall exercise with respect to the Confidential Information of the other party the same degree of care as the party exercises with respect to its own confidential or proprietary information of a similar nature, but in no event
less than reasonable care, and shall not disclose it or permit its disclosure to any Third Party, other than: (i) to its Affiliates, and those of its and its Affiliates’ respective employees, Sublicensees, consultants, contractors,
accountants, attorneys, advisors and agents, as well as to any potential acquirers, investors or lenders and their respective advisors, in each of the foregoing cases who have a need to know and who are bound by materially similar obligations of
confidentiality and non-use as those of this Agreement and (ii) by or on behalf of Suneva to any applicable Regulatory Authority in connection with the regulatory approval process for any Product. Each
party shall be responsible for any breaches of confidentiality by any of its Affiliates, or its Affiliates’ respective employees, Sublicensees, consultants, contractors, accountants, attorneys, advisors or agents, or any potential acquirers,
investors or lenders or their respective advisors. 
 14.1.2 Exceptions 

However, such undertaking of confidentiality (as described in Section 14.1.1) shall not apply to any information or data which: 

 

	 	(i)	 the receiving party lawfully receives without obligation of confidentiality at any time from a Third Party
lawfully in possession of same and having the right to disclose same; 

  

	 	(ii)	 is, as of the Effective Date, in the public domain, or subsequently enters the public domain through no fault
of the receiving party; 

  

	 	(iii)	 is independently developed by the receiving party as demonstrated by written evidence without reference to or
benefit of information disclosed to the receiving party by the disclosing party; or 

  
 -28- 

 Confidential 

 

	 	(iv)	 is publically disclosed pursuant to the prior, written approval of the disclosing party. 

14.1.3 Required Disclosure 
 If a party is
required to disclose any Confidential Information of the other party pursuant to Applicable Law or legal process, the first party shall (i) give prior, written notice of such required disclosure to the other party, to the extent reasonably
practicable, (ii) give reasonable assistance to the other party, if requested thereby, seeking confidential or protective treatment thereof, and (iii) only disclose such Confidential Information to the extent required by such Applicable
Law or legal process based on the advice of such party’s legal counsel; provided, however, that the foregoing requirement shall not apply with respect to any disclosures by Suneva to any applicable Regulatory Authority in connection with the
regulatory approval process for any Product. 
 ARTICLE 15 

General Provisions 

15.1 Relationship of the Parties 
 Nothing
herein shall be deemed to establish a relationship of principal and agent between Histogen and Suneva, nor any of their agents or employees for any purpose whatsoever. This Agreement shall not be construed as creating a partnership between Histogen
and Suneva, or as creating any other form of legal association or arrangement, which would impose liability upon one party for the act or failure to act of the other party. No employee or representative of a party shall have any authority to bind or
obligate the other party to this Agreement in any manner whatsoever, or to create or impose any contractual or other liability on the other party without said party’s approval. For all purposes, the parties’ legal relationship under this
Agreement to each other shall be that of independent contractors. 
 15.2 Assignment 

This Agreement and the rights and duties appertaining hereto may not be assigned or otherwise transferred by either party without first obtaining the written
consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. However, if a party is acquired by a Third Party, or if substantially all of the assets of a party are acquired by a Third Party, then the party
may assign its rights and obligations to said acquiring Third Party without the consent of the other party. 
 15.3 Binding Nature and
Inurement 
 This Agreement is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns. For the
avoidance of doubt, a Change of Control will not terminate and is not grounds for termination of this License Agreement or the Supply Agreement. 

  
 -29- 

 Confidential 

 

 15.4 Entire Agreement; Amendment 

The parties hereto acknowledge that this Agreement (including the Schedules hereto and the Supply Agreement) sets forth the entire agreement and understanding
of the parties hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument signed by the parties hereto, and shall supersede all previous communications,
representations or understandings, either oral or written, between the parties relating to the subject matter hereof, including the Original Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon
the parties hereto unless reduced to writing and signed by the respective authorized officers of the parties. 
 15.5 Further Assurances

 From time to time during the Term, at the reasonable request of either party, the other party shall execute and deliver such documents and take such
other action as the requesting party may reasonably request to consummate more effectively the transactions contemplated hereby. 
 15.6
Governing Law 
 This Agreement, and any disputes arising directly or indirectly from this Agreement, shall be governed by and construed and enforced in
accordance with the laws of the state of California, without regard to its conflict-of-laws rules. The parties agree that any claims arising under this Agreement shall
be exclusively venued in the state and federal courts located in San Diego County, California. Each party hereby irrevocably submits to the exclusive jurisdiction of such courts for any such claims, and waives any objections to the laying of venue
in such courts. Unless expressly provided otherwise, each right and remedy in this Agreement is in addition to any other right or remedy, at law or in equity, and the exercise of one right or remedy will not be deemed a waiver of any other right or
remedy. 
 15.7 Public Announcements 

Except as may be expressly permitted under Article 14 or mandated by Applicable Laws or the rules of any stock exchange, neither party will make any public
announcement of any information regarding this Agreement without the prior written consent of the other party. Once any statement is approved for disclosure by the parties, either party may make a subsequent public disclosure containing the same
information disclosed in such prior public announcement without further approval of the other party. 
 15.8 Notices 

All notices, claims, demands and other communications hereunder shall be in writing and shall be deemed given if delivered personally, one (1) business
day after being sent by major overnight courier, or four (4) business days after being mailed by registered or certified mail (postage prepaid, return receipt requested) to each party at its respective address set forth below ( or at such other
address as any party hereto shall hereafter specify by notice in writing to the other parties hereto). 
 If to Histogen: 

10655 Sorrento Valley Road 

San Diego, CA 92121 

  
 -30- 

 Confidential 

 

 Attn: President 

With a copy to: 
 DLA Piper

 4365 Executive Drive, Suite 1100 

San Diego, CA 92121 
 Attn: Knox
Bell 
 If to Suneva: 

5870 Pacific Center Blvd 

San Diego, CA 92121 

Attn: Nicholas L. Teti, Jr., CEO 

With a copy to: 
 5383
Hollister Avenue, Suite 260 
 Santa Barbara, CA 93111 

Attn: Stewart M. Brown, VP & General Counsel 

15.9 Payment of Own Fees and Expenses 

Each of Suneva and Histogen shall be responsible for their own expenses relating to the preparation and consummation of this Agreement and, except as specified
herein, the agreements and transactions contemplated hereby. 
 15.10 Severability 

The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under
any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof. 

15.11 Waiver 
 The failure of either party
to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. Any
waiver of any rights or failure to act in a specific instance must be, with respect any waiver, provided in writing to be effective and relates only to that instance and is not an agreement to waive any rights or fail to act in any other instance.

  
 -31- 

 Confidential 

 

 15.12 Headings 

The headings of the several articles are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. Unless the context of this Agreement otherwise requires, the use of the terms “include”, “includes” and “including” are not limiting. 

15.13 Counterparts; Facsimile 
 This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be signed and delivered to the other party by facsimile
signature; such transmission will be deemed a valid signature. 
 [Signature page follows]

  
 -32- 

 Confidential 

 

 IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated License Agreement by
their duly authorized representatives. 
  

									
	SUNEVA MEDICAL, INC.	 		 	 HISTOGEN, INC.

					
	By:	 	 /s/ Nicholas L. Teti, Jr.
	 		 	By:	 	 /s/ David Nassif

	Name:	 	Nicholas L. Teti, Jr.	 		 	Name:	 	David Nassif
	Title:	 	Chairman & CEO	 		 	Title:	 	President

  
 -33-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]